

Dr. Martin Mackay

President, Pfizer Global Research & Development



Martin Mackay is the President of Pfizer Global Research and Development (PGRD). Martin oversees more than 9,000 employees spanning across the globe, 9 therapeutic areas and several functional lines (Research, Development Operations, Regulatory Affairs and Quality Assurance, Pharmaceutical Sciences, Drug Safety, etc). Martin began his career at Pfizer in 1995 as the Director of Discovery Biology in the UK. In 2007, he was named Vice President PGRD, Head of Worldwide Development. He was appointed to his current role in September of 2007.

Prior to coming to Pfizer, Martin earned a Microbiology First Class Honors Degree at Heriot-Watt University and a PhD in Molecular Genetics at the University of Edinburgh in 1983. Between degrees he worked in Antibacterial Discovery at Beecham Pharmaceuticals in Surrey, UK. Martin joined the Advanced Drug Delivery Research Unit at Ciba-Geigy in Sussex, UK and became the Head of Drug Preformulation and Delivery at that site. In 1993, he moved to Ciba's headquarters in Basel, Switzerland as Head of Molecular and Cell Biology, CNS Research, where he led an international team of researchers until his move to Pfizer in 1995.

Title: Directed Evolution of Pharmaceutical and Biotherapeutic R&D

Mr. Stefan Borgas

CEO, Lonza Group Ltd.

Undergraduate in business administration from the University of Saarbrücken, Graduate from University of St.Gallen, Switzerland, specializing in marketing and management.



Joined Lonza in June 2004 as Chief Executive Officer

BASF Fine Chemicals 1998 to 2004

- 2003 to 2004 NJ, USA, Group Vice President, Fine Chemicals Northamerica
- 2001 to 2003 Ludwigshafen, Germany, Group Vice President, Fine Chemicals Europe
- 1998 to 1998 Ludwigshafen, Germany, Director Strategic Marketing Animal Nutrition

BASF Engineering Plastics 1990 to 1998

- 1995 to 1998, NJ, USA, Group Logistics Manager Engineering Plastics
- 1993 to 1995, NJ, USA, Product Manager Engineering Plastics
- 1990 to 1993 various positions in marketing and sales in Germany, Ireland and China

Title: Global biomanufacturing in a challenging time - Delivering sustainable values while weathering out the perfect storm

Dr. Swaminathan Subramaniam

*Director, Licensing & External Research
Merck & Co., Inc.*



Dr. Swami Subramaniam's role is to identify partnering opportunities that fit with Merck's strategic research and development objectives in key franchise areas. Such opportunities may reside in universities, start-up companies, government institutes or established bio-pharma firms within India. He is one of several licensing "ambassadors" deployed by Merck to biomedical innovation clusters throughout the world. As part of Merck's global licensing team, the regional scientific assessment professionals build relationships, provide guidance on Merck's licensing interests, and serve as a local contact for companies and institutions with which Merck can collaborate to develop best-in-class therapeutics for serious unmet medical needs.

Dr. Subramaniam is a physician who developed his research interests in clinical pharmacology and neuropharmacology during his postgraduate training at the Postgraduate Institute of Medical Education and Research, Chandigarh, followed by doctoral training at the University of Pennsylvania and postdoctoral training at the National Institute of Neurological Disorders and Stroke. Swami returned to India in 1995 to join Dr Reddy's in their discovery research program. He held varied responsibilities both on the scientific and commercial sides while at Dr Reddy's, including Founder and Managing Director of a subsidiary company, Aurigene. After holding leadership positions at Sanmar Speciality Chemicals and Rheoscience A/S, he joined his present position at Merck Research Laboratories in 2008.

Title: Business Drivers leading to Collaborations & Licensing

Dr. Reid Leonard

Director, Research and Licensing, Merck & Co., USA


Dr. Reid Leonard is the Executive Director, External Research and Licensing for the Merck Research Laboratories, Merck & Co., Inc. Reid's role is to identify partnering opportunities that fit with Merck's strategic research and development objectives in key franchise areas. Such opportunities may reside in universities, start-up companies, or established bio-pharma firms



within the Eastern U.S. He is one of several licensing "ambassadors" deployed by Merck to biomedical innovation clusters throughout the world. As part of Merck's global licensing team, the regional scientific assessment professionals build relationships, provide guidance on Merck's licensing interests, and serve as a local contact for companies and institutions with which Merck can collaborate to develop best-in-class therapeutics for serious unmet medical needs.

Dr. Leonard's research career in neuroscience and cell physiology began while an undergraduate at Brandeis University where he earned a B.A. in Biology and Psychology. Reid subsequently earned a Ph.D. in biology from Purdue University and completed postdoctoral training in molecular pharmacology at the California Institute of Technology. He joined Merck Research Laboratories in 1989 to carry out basic and discovery research on ion channels and moved into the scientific licensing organization in 1998. Since that time, Reid has held a variety of positions contributing to the identification, scientific assessment, and execution of academic and biotech partnerships for Merck & Co., Inc.


Title: Collaborating to Win

Name	Prof. Abbas S. Lotfi	
Present Position & Affiliation	Director, National Institute of Genetic Engineering & Biotechnology (NIGEB) Iran	
Email	Lotfi-ab@nigeb.ac.in	
Phone	+98-21-44580396-98	
Fax	+98-21-44580399	
Professional Experience	Professor in Biochemistry	
Area of Research	Protein and Enzymes Biotechnology	
Major Contributions	As part of NIGEB decisions, expansion of the international collaboration is a principal policy, focuses on cooperation between developing countries.	
Number of Publications	80	
Highlights of achievements	1. The inborn error of metabolism (Alpha 1-antitrypsin deficiency), genotyping and family study,	
	2. Alpha 1-Antitrypsin deficiency and related diseases	
	3. Production of recombinant enzymes for enzyme therapy	
	4. Conformational diseases: Serpins and Neuroserpin	
Education	Ph.D in Tehran University for Medical Sciences, Clinical Biochemistry	
Post Doc	H.E.J. Research Institute for Chemistry, Protein Chemistry Section, Karachi, Pakistan	
Professional Association	The editor in chief of Iranian Journal of Biotechnology.	

Title: Biotechnology Intellectual Property: Opportunities and Challenges for Developing Countries

Prof. Brian F Clark

Vice President, European Federation of Biotechnology, Barcelona



Brian F. C. Clark has held the position of Vice President of the EFB since 2006. During his long career span of nearly four decades, he has held Professorship of biostructural chemistry at the University of Aarhus, Denmark; was a member of Scientific Staff, Medical Research Council, Laboratory of Molecular Biology, Cambridge and also held the membership of division of cell biology under the direction of Francis Crick & Sydney Brenner. He won the Gold Medal for Peace and Science, Albert Schweitzer International University in 2001 and Copernicus Medal from the Polish Academy of Sciences in 2005. His achievements include Discovery of the Initiation Codon for protein synthesis and hence start of protein coding (1965-66); first crystallisation of tRNA (1968); determination of the first structure of a GTP-binding protein (1985) and structural determination of the ternary complex (1995).

Title: Role of the European Federation of Biotechnology (EFB)

Dr. Ravi Sodha

Senior Director, Business Development, Actelion Pharma, Switzerland

Dr. Sodha studied in the UK obtaining B.Sc. in Pharmacology, Ph.D. and MBA. He started his career in basic research almost 25 years ago, first at London University, then at Zurich University Hospitals and later Ciba Geigy Basel.



In 1995, he moved to Clinical Development at SmithKline Beecham. In 1997, he joined Novartis Pharma Sales & Marketing and in 1999 moved to Business Development & Licensing, where he spent 8 years in various functions and activities. He was responsible for licensing activities in the emerging growth markets, including India, China, Korea and Taiwan. Dr. Sodha joined Actelion in the present capacity in 2008.

(Session III)

Innovative solutions to Funding challenges

Mr. Sarath Naru

Managing Partner, APIDC Venture East, Hyderabad



Sarath has been focused on venture capital/private equity in India for more than ten years, investing in rapidly growing businesses across tech, biotech, and manufacturing sectors. He is the Managing Partner of VenturEast Funds which has over \$300 million under management. VenturEast has consistently raised funds with a pioneering investment focus.

Prior to this, Sarath built a trading and manufacturing business spanning the USA and India. He also gained significant experience working for Procter & Gamble in the area of brand management (marketing & general management) in the USA, and in manufacturing with British American Tobacco subsidiary (VST Industries). His academic qualification includes a Bachelor of Technology (B.Tech.) from IIT, Madras and MBA (Finance) from University of Chicago.

Sarath has been actively supporting technology development and venture capital with active involvement in various industry organizations. He has been a past-secretary of the Indian Venture Capital Association, and is a member of the Investment Committees of UTI Ventures funds (Subsidiary of India's largest Mutual Fund Manager) and previously of Avigo Ventures Dubai (sponsored by the Lord Bagri group of the UK). He is the Chairman of the Agri-Business Incubator at ICRISAT, Hyderabad, (elected the best incubator in India in 2006), and is a member of the Governing Board of ICICI Knowledge Park Incubator. He is the treasurer of Association for Biotech Lead Enterprises (ABLE) and is an Executive Committee member of the PanIIT Association.

Dr. Aditya Kapil

Principal, APIDC Venture East, Hyderabad



Dr. Aditya Kapil has significant life sciences exposure both in India and overseas (UK & US). He leads the early-stage drug discovery deals in Ventureeast's life sciences portfolio. Dr. Kapil has deep experience in setting up Indian operations for overseas companies that benefit from Indian scientific and operational advantages. He has added significant value to such companies, including setting up labs from scratch and hiring key management. Dr. Kapil has helped Ventureeast's portfolio in-license drugs at various stages of development. Dr. Kapil has also forged collaborative deals between drug discovery companies in the West and Indian academia to access Indian synthetic chemistry and molecular biology manpower and skills.

Prior to Ventureeast, Dr. Kapil was part of the founding team of Jubilant Biosys, a leading Indian biotechnology company with 500+ employees. At Jubilant he led a team of 25 professionals that built the first commercialized gene-protein database out of India. Its current avatar, PathArt®, is used by leading US biotech and pharma companies to alleviate early stage bottlenecks in drug discovery.

Dr. Kapil did his Ph.D. in biochemistry at the University of York in UK, followed by post-doctoral stints at the University of Chicago and the National Center for Biological Sciences in India.

Dr. Jasmine Patel

Managing Director, FIL Capital Advisors, Mumbai



Dr. Jasmin Patel is Managing Director at FIL Capital Advisors (India), Fidelity's Private Equity and Growth Capital Fund focused on India. In this role, he drives investments into the lifesciences sectors including pharma, biotech, services and devices by the Fidelity team of 7 experienced professionals based in Mumbai and together with another 20 lifescience focused investor colleagues in other parts of the world.

From 2005-2007, he was Chief Operating Officer for the Indian business of leading pharmaco Novartis. Dr. Patel spearheaded a transformational strategy for Novartis in India with the set up of a new customer-centric business. Prior to assuming these responsibilities Dr. Patel was the Head of Disease Area Strategy and M&A Assessments for 2 years at Novartis global headquarters in Basel.

From 2000-2003, Dr. Patel held positions of increasing responsibility with McKinsey & Company in New Jersey where his clients were among the world's leading players in the pharmaceutical, biotech and healthcare industries. He has advised on diverse areas including R&D strategy, new product commercialization, market entry strategy, business development, marketing strategy, organizational design, and post-merger integration.

Prior to these managerial experiences, Dr. Patel was a scientist in the Pharma and biotech sectors. For 6 years in the 1990's, with Chugai Biopharmaceuticals and Gen-Probe in San Diego, he led multiple initiatives that included the set up of a new gene-based therapy venture and the clinical development of a novel antisense agent for the treatment of AIDS.

Dr. Patel has a B.Pharm degree from Bombay University (gold medalist), a Ph.D. in Medicinal Chemistry with honors from the U.S., and an MBA from Wharton. He also spent 2 years as a PPG Post-doctoral Fellow at the world renowned Scripps Research Institute in California.

His scientific accomplishments include: 8 US and International patents; 20 published papers, reviews, articles and abstracts; and more than 30 presentations at international scientific congresses and business conferences.


Dr. Patel has served in leadership roles in organizations like the American Association of Pharmaceutical Scientists, The Scripps Society of Fellows, on professional boards that include the San Diego Pharmaceutical Forum, American Chemical Society, and as reviewer for various scientific publications.

Dr. Prasad Sunkara

CEO, Innova Therapeutics, Inc, USA



Dr. Prasad Sunkara, a serial entrepreneur, combines over 30 years of corporate, financing, business development, research, development and management experience in cancer, cardiovascular and CNS disease indications at Marion Merrell Dow pharmaceuticals (now Sanofi Aventis) and eight other successful start up biotech companies in California and Michigan. He received a PhD in microbial biochemistry from Indian Institute of Science and a post doctoral fellowship in cell and tumor biology at M.D.Anderson Cancer Center, Houston, Texas. His areas of research include pharmaceutical drug discovery and preclinical and clinical development of oncology drugs. He helped in discovery of and development of a number of oncology, CNS and autoimmune drug candidates. He has 140 publications and 35 patents to his credit.

Name	Dr. Chris Lowe	
Present Position & Affiliation	Director, Institute of Biotechnology, Cambridge University, UK	
Email	cr11@biotech.cam.ac.uk	
Phone	01223-334160	
Fax	01223-334162	
Professional Experience	<ol style="list-style-type: none"> 1. More than 40 years of teaching experience at various levels and conducts specialist courses in Australia, Argentina, Chile, France, Italy, India, Portugal, Russia and Sweden. 2. Holds two visiting chairs at the Universities of Lund and Bath. 	
Area of Research	Downstream Processing of biopharmaceuticals /Proteomics; Biosensors/Bioelectronics and anobiotechnology; Enzyme, Protein and Microbial Technology	
Major Contributions	Has been involved in creating a seamless interface between academia and industry and developing new mechanisms designed to transfer quality science from the academic to the private sector; the Institute of Biotechnology is a working example of this.	
Number of Publications	312	
Patents	More than 60	
Highlights of achievements	1. Recipient of 9 awards and have been awarded fellowship of leading institutions	
	2. Played an active and strategic role as a member of a number of UK and overseas grant awarding agencies since 1981, reviewing substantial research proposals from Australia, Canada, Hong Kong, Israel, New Zealand, Sweden, Switzerland and USA.	
	3. During 1984-2006 received a total grant of £14,794,843	
Education	Ph.D in Biochemistry	
	Postdoctoral Research Associate: University of	

	Liverpool
Professional Association	
Membership	Associated with 17 academic journals over the last three decades
	Has served on a number of government committees

(Session V)

Partnerships in Drug Discovery in Asian Countries: Case Studies

Dr. Krishna M. Ella

Chairman and Managing Director, Bharat Biotech Ltd., Hyderabad



Dr. Krishna M. Ella, moved back to India in 1996 after completing higher studies at the University of Hawaii, The University of Wisconsin-Madison and serving as Asst. Professor at the Medical University of South Carolina in USA. His quest for uniqueness has transformed him into a Bio-entrepreneur, which leads to the birth of Bharat Biotech International Ltd at Hyderabad. Till date, Bharat invested \$40 Million in manufacturing facilities and \$ 12 Million in R&D costs with 8 different vaccines and five biopharmaceuticals in the market. Dr. Ella filed more than 20 Global Patents on new molecules, protein folding and formulation.

Dr. Ella was awarded more than 100 National and International awards including Asia Pacific BioBusiness Leadership Award 2005 (University of Southern California), Best Entrepreneur Award and Business World & Marico Foundation Innovation Award. Dr. Ella obtained various Research Grants from Bill & Melinda Gates Foundation and other international agencies. Dr. Ella was invited in the Rashtrapati Bhavan to meet President & First Lady George Bush during their February visit. Dr. Ella received The US-Health Secretary and US-FDA Commissioner Chose at Bharat Biotech Facility during 2008 to discuss on Innovation and Drug Discovery.

Dr. Ella was instrumental and advised the Government in setting up Biotech Park in Hyderabad. For the last Five years he was the Co-Chairman Indo-USA High Technology Cooperation Group (HTCG) on behalf of Govt. of India and facilitated Knowledge initiative bill signed by two countries. He gave more than 300 lectures to motivate young Indians on topics like Innovation, Bio-entrepreneurship and Regulatory issues. On February 15, 2008, he received Best Technology and INNOVATION award from The Prime Minister of India.

Dr. Ella believes to make India as a strong Biotech country. He moved on setting up BSL-4 containment manufacturing facility (BIOVET) which will be second one in the world in Bangalore.

Mr. Swapan Bhattacharya

Managing Director, TCG Lifesciences Limited, Kolkata



Swapan Bhattacharya is the Managing Director of TCG Lifesciences Limited, a leading life sciences R&D services and informatics company in India and part of the New York based private equity firm of The Chatterjee Group ("TCG"), sponsored by Dr. Purnendu Chatterjee. Mr. Bhattacharya has been with TCG since 1995 and has played a key role in expanding TCG's investments in India, by identifying and developing opportunities, negotiating and closing transactions and monitoring investment performance. In 2001, he took the responsibility to expand TCG's life sciences business in India and has successfully positioned TCG Lifesciences as one of the leading life sciences contract research services and informatics organization providing integrated end-to-end solutions to the global life sciences industry for discovery and development of superior drugs and biologics. He is also on the Board on various TCG companies.

Prior to joining TCG, Mr. Bhattacharya was a corporate finance and mergers and acquisitions specialist for PaineWebber Inc. (currently UBS PaineWebber) in New York from 1987 to 1995. In such capacity, he managed the firm's investment banking activities in India, providing advisory services in several cross border transactions. From 1980 to 1987, Mr. Bhattacharya was Advisor to the U.S. Nuclear Regulatory Commission where he was responsible for developing strategies in the disposal of nuclear materials and waste.


Mr. Bhattacharya is also the Co-Chairman of the biotechnology committee of Federation of Indian Chambers of Commerce and Industry ("FICCI") as well as a board member of West Bengal Electronics Industry Development Corporation Limited ("WEBEL"), the nodal IT/IT infrastructure arm of the Government of West Bengal. He is a member of the International WHO'S WHO Historical Society.

Mr. Bhattacharya received a B.Tech from the Indian Institute of Technology, Kharagpur, an M.S. from Virginia Polytechnic Institute and State University, and a M.B.A. from Kellogg School of Management, Northwestern University. He received the Lester Cunningham Award for academic excellence at Northwestern. He has been recently awarded Udyog Rattan Award from Institute of Economic Studies for his outstanding contribution in India's industrial development.

Dr. Rashmi.H. Barbhaiya, Ph.D

MD & CEO Advinus Therapeutics, Bangalore


Rashmi H. Barbhaiya, Ph.D. is a Pharmaceutical Executive with 27 years of experience in Pharmaceutical R&D. He is one of the founders, CEO and Managing Director of Advinus Therapeutics, a research-based pharma company located in Bangalore and Poona, India.



Dr. Barbhaiya started his industrial pharmaceutical career in 1980 with Bristol-Myers Company in the United States where he spent next 21 years. He took an early retirement from BMS in 2001. His last position was Vice President in the pharmaceutical Research Institute.

In the year 2002, he returned to India to join Ranbaxy as the President of R & D and led a team of over 900 professionals involved in generic, drug delivery, herbal and innovation-driven new drug research and development activities. He was instrumental in creating an R & D alliance between Ranbaxy and GSK, the first of its kind for an Indian company. He is also credited for creating an alliance between Medicine for Malaria Venture (MMV) and Ranbaxy for developing a novel antimalarial which is undergoing clinical trials at this time.

He obtained the Ph.D. degree in Clinical Pharmacology from the St. Bartholomew's Hospital Medical College, University of London. He continued his education through post-doctoral training at the University of Florida and University of Wisconsin. His scientific contributions have resulted in over 150 publications. He has served on the Editorial Boards of Antimicrobial Agents and Chemotherapy and Biopharmaceutics and Drug Disposition journals. Dr. Barbhaiya has received a number of awards for his scientific contributions. Some of these include AAPS Fellow, AAPS Meritorious Manuscript Award, AAPS Outstanding Achievement Award, Ranbaxy Award for Excellence in Pharmaceutical Research and India Life Sciences Person of the Year 2007 by Burrill & Company.

<p>Name</p> <p>Present Position & Affiliation</p>	<p>Dr. Hartmut Kühn,</p> <p>Professor, University Medicine Berlin Charité, Manhijoustr., Berlin, Germany</p>	
<p>Professional Experience</p>	<p>With a teaching and research experience of nearly 30 years, he is currently research group leader at the Institute of Biochemistry, University Medicine Berlin – Charité.</p>	
<p>Area of Research</p>	<ol style="list-style-type: none"> 1. 1981 - Promotion (Dr. med., M.D.): Isolation and characterization of a lipoxygenase activity in lungs and its identification as hemoglobin effect. The quasi-lipoxygenase activity of hemoglobin. 2. 1986 - Habilitation (Dr. sc. med., D. Sci.): The lipoxygenase pathway of arachidonic acid cascade. Investigations into the mechanism of the lipoxygenase reaction and on the occurrence of lipoxygenases in animal tissues. Lipoxygenase inhibitors as potential drugs. 3. 1989 - Facultas docendi: Concepts of practice training of medical students in biochemistry. 	
<p>Number of Publications</p>	<p>Around 400</p>	
<p>Highlights of achievements</p>	<ol style="list-style-type: none"> 1. Lessing-Award in Gold (Ministry of Education of German Democratic Republic) (1979) 2. Humboldt-Awards, research award of Humboldt University Berlin (1979 and 82) 3. Virchow-Award of the Ministry of Health of German Democratic Republic (1983) 4. Lohmann-Award of the Biochemical Society of German Democratic Republic (1989) 	
<p>Education</p>	<p>MD, D. Sci.) at the University Clinics Charité, Humboldt University, Berlin</p>	
<p>Professional Association</p>		
<p>Membership</p>	<p>Member of the editorial board of J. Biol. Chem.</p>	


Dr. Manni Kantipudi

President, GVK Bio, Hyderabad

Manni Kantipudi joined GVK BIO as the President in 2007. He brings a unique blend of services, international management and product development experience. He has done his Bachelors in Computer Engineering and Masters in Computer Science. He has spent 15 years with Intel Corporation in various leadership positions in the US and Asia. He was responsible for setting up Intel's engineering presence in India. He was CIO of Intel for Asia where he managed a large team of professionals servicing the IT needs of the greater Asia region. He was Director of Software for Intel's Centrino product line (one of the most successful product lines for Intel) where he brought to market successful products in high volume.



Session VII
Oncology & Monoclonal Antibodies

Name Present Position & Affiliation	Dr J Gowrishankar Director, CDFD, Hyderabad 
Professional Experience	He was a Scientist (Group Leader), Centre for Cellular and Molecular Biology, Hyderabad; has been associated with Centre for DNA Fingerprinting and Diagnostics since 2000.
Area of Research	Microbial genetics; molecular biology; biotechnology
Number of Publications	42
Patents	4
Highlights of achievements	Recipient of 9 awards - includes <ol style="list-style-type: none"> 1. Young Scientist Awards of INSA and CSIR, 1986 & 1987. 2. B M Birla Award for Biological Sciences, 1991. 3. Shanti Swarup Bhatnagar Prize in Biological Sciences, 1997. 4. New Millennium Medal of Indian Science Congress Association, 2000. 5. Shri Om Prakash Bhasin Award for Science & Technology, 2005 Elected to Fellowships of Indian Academy of Sciences (1992), National Academy of Sciences (India) (1996), Indian National Science Academy (2001) & Andhra Pradesh Akademi of Sciences (2004).
Education	MBBS, Ph.D

Dr. Robert W. Naismith

Chairman & CEO, Roosevelt Capital Partners, LLC, PA, USA

Dr. Naismith serves as Chairman and CEO of Roosevelt Capital Partners, LLC. Formerly he served as Chairman and CEO of Life Science Analytics and Managing Director of London-based Datamonitor, Inc. Dr. Naismith co-founded Pharmakon Research International, Inc., a major international preclinical contract research organization. In 1986 he founded Biofor, Inc., a biopharmaceutical company, and



served as its President and Chief Executive Officer until its sale to Scherer Healthcare in 1995. From 1996 to 1998, Dr. Naismith served as Chairman and Director of the MicroCap Fund and Managing Director of Healthcare at Bluestone Capital Partners, L.P. in New York, before founding Emedsecurities, a boutique investment bank serving the small-cap life-science industry. Emedsecurities was the predecessor to Life Science Analytics, which he sold to Datamonitor in 2006.

Dr. Naismith serves as a Director of Penn Security Bank, St. Charles Pharmaceuticals, and the Life Sciences Greenhouse of Central PA; a Trustee of the William Harvey Research Institute; and a member of the Kania School of Management's Advisory Board at the University of Scranton. In addition, Dr. Naismith is a founding member and Vice Chairman of the Board of the Commonwealth Medical College a new allopathic medical school serving northeastern Pennsylvania. An adjunct associate professor in the School of Medicine at Case Western Reserve University and The Commonwealth Medical College, Dr. Naismith holds a Ph.D. in genetics from the Pennsylvania State University.

Title: BioSimilar: An opportunity in waiting

Dr. Vijay Ramakrishnan

Founder & CEO, PIKAMAB, Inc., CA, USA

Email: vijay@pikamab.com




Dr. Ramakrishnan has twenty one years of combined experience in protein biotechnology research; equity research and investment banking in biotechnology industry; and in building biotechnology companies with a particular emphasis on the discovery and development of therapeutic antibodies, antibody engineering, and stratified medicine. He is the founder of Palo Ventures, a venture fund specializing in building innovative healthcare biotechnology companies that integrate US/India R&D model.

By correlating clinically relevant genotypes to the mechanism of action by which certain marketed therapeutic antibodies work in patients, Dr. Ramakrishnan proposed a rational way to stratify patient populations into distinct patient groups. Incorporating this approach has profound implications for the future treatments of cancers, autoimmune diseases, and infectious diseases. He is the inventor of several patents related to the application of stratified medicine in drug discovery and development, antibody engineering, diagnostics, patient selection and treatment strategies. He was responsible for identifying, evaluating, and in-licensing antibody engineering technologies from Stanford University and the University of Texas at Austin. He is also an inventor of Penetrabodies, the chimeric antibody molecules designed for receptor-mediated intracellular delivery of therapeutic antibodies.

Prior to founding Pikamab, Dr. Ramakrishnan had a short stint as the Vice President of biotechnology investment banking at an emerging growth investment bank, and had the opportunity to evaluate business strategies and product portfolios of several private and public biotechnology companies. He is a member of the editorial board of the scientific journal, mAbs.

Dr. Ramakrishnan has ten years of experience investigating the microbiology and biochemistry of anaerobic microorganisms isolated from deep sea volcanic vents (hyperthermophiles). He investigated the mechanisms of thermal stability of these proteins at near-boiling temperatures, and through collaborative efforts, several novel proteins and enzymes were investigated for their commercial applications. Dr. Ramakrishnan has earned a PhD in Microbiology from the University of Georgia, Athens, GA. As a Post Doctoral Scholar at California Institute of Technology, he continued to work on the structure-function relationships of metalloproteins, and membrane proteins. Dr. Ramakrishnan has completed Engineering and Technology Management Programs at Caltech.

Title: Stratified Medicine: A Rational Drug Development and Treatment Paradigm

Name	Dr. Amitabha Chaudhuri	
Present Position & Affiliation	Scientist, Genentech, Inc	
Email	amitabha@gene.com	
Phone	650-467-8695	
Professional Experience	Has been associated with the: <ol style="list-style-type: none"> 1. Department of Proteomics and Biomarkers CuraGen Corporation, Branford, CT (2001-2004) 2. Department of Molecular Oncology Genentech, Inc., CA (2005-present) 	
Area of Research	Biology of receptor tyrosine kinases in cancer	
Major Contributions	<ol style="list-style-type: none"> 1. Generation and maintenance of cell polarity in yeast 2. Protein-protein interaction map of Drosophila 3. Developed a new method of analyzing microarray data (PADGE) to discover novel cancer targets 4. Mechanism of receptor tyrosine kinase signaling 	
Number of Publications	15	
Highlights of achievements	1. Developed large-scale method of purifying recombinant human streptokinase (IMTECH, Chandigarh)	
	2. Described Drosophila proteome map in Science	
	3. Developed new statistical methods to gain confidence in protein interaction networks and utilized them to identify new drug targets	
Education	PhD, Department of Biochemistry, Indian Institute of Science Bangalore	
Post Doc	Department of Gastroenterology, Massachusetts General Hospital, Harvard Medical School (1996-1999) Department of Molecular Biology, Harvard University (1999-2001)	

Title: Understanding cancer biology in search of novel targeted therapies

Dr. Shireen Vali


Co-founder and Chief Scientific Officer, Cellworks Group Inc., CA, USA

Shireen, a Cellworks co-founder is a member of the senior executive team. She manages Cellworks Research and Development groups. She has over 16 years experience in research aligned to pharmaceutical, diagnostics and professional education fields at UC Davis, Stanford, BioGenex and Institute of Bioinformatics & Applied Biotechnology (IBAB). She serves on the Board of Cellworks Research India Limited (CRIL).


Her past professional experience include studying signal transduction pathways involved in the neural activity-dependent regulation of metabolic gene expression in skeletal muscle; applied research in the area of Cystic Fibrosis; setting up and managing the framework for the Online Continued Medical Education (CME) program; histopathology and systems virtual prototyping of Biology at the bio-chemical and pathway abstraction level. She holds a PhD in Neurobiology from University of California, Davis and is currently also an adjunct faculty at IBAB.



Title: Mapping Tumor Signature to Personalized Therapy - Oncology Case Study based on mTOR Inhibitor

<p>Name</p> <p>Present Position & Affiliation</p>	<p>Dr. Barry Furr, Former Chief Former Chief Scientist, AstraZeneca, UK</p>	
<p>Professional Experience</p>	<ol style="list-style-type: none"> 1. He is a reproductive biologist and endocrinologist by training who worked for over 33 years at AstraZeneca and its associate companies. 2. Fellow of the Academy of Medical Sciences and Institute of Biology, and has an honorary chair at the University of Manchester. 3. A William Pitt Fellow at Pembroke College, Cambridge and a Trustee of the Breast Cancer Campaign and member of the CRUK Council Research Strategy Committee. 	
<p>Major Contributions</p>	<p>He worked on the antioestrogenic breast cancer drug, tamoxifen, and both Zoladex and Casodex for prostate cancer were discovered in his laboratory.</p>	
<p>Number of Publications</p>	<p>More than 160</p>	
<p>Highlights of achievements</p>	<ol style="list-style-type: none"> 1. Awarded Officer of the Order of the British Empire (OBE) for services to cancer drug discovery (2000) 2. The Society for Drug Research Award for Drug Discovery for the discovery and development of Zoladex (1991) 3. He is now a consultant for a number of important companies, including AstraZeneca, Abingworth, Modern Bioscience, SV Life Sciences and Astex, and is a non-executive Director of Genus and the MHRA. 	
<p>Education</p>	<p>Ph.D. in Reproductive Endocrinology</p>	
<p>Professional Association</p>		
<p>Membership</p>	<p>More than 40 in professional associations and academic institutes</p>	
<p>Reviewer</p>	<p>More than 12 journals. Guest Editor of Clinics in Oncology on Hormone Therapy (1982) and Prostate Cancer(1988); Editor (with A E Wakeling) of Pharmacology & Clinical Uses of Inhibitors of Hormone Secretion and Action.</p>	

(Session IX)
Vaccines: India's Strength

Name Present Position & Affiliation	Dr. K. I. Varaprasad Reddy CEO, Shantha Biotechniques, Hyderabad	
Professional Experience	Left government service in 1985 to become an Entrepreneur by joining Hyderabad Batteries Ltd. Co-promoted Sabnife Power Systems Limited, an Indo-Swedish joint venture for development and production of High Technology based batteries for Defence applications – like Submarine batteries, MIG Air Craft batteries, etc. In 1992, he promoted Shantha Biotechnics Private Limited.	
Area of Research	Developing recombinant based vaccines and therapeutic proteins for human healthcare.	
Major Contributions	<ol style="list-style-type: none"> 1. India's first genetically engineered product "SHANVAC-B" vaccine against Hepatitis-B 2. India's first indigenous recombinant "Interferon Alpha-2b" - the therapeutic drug for the treatment of various types of Cancer 3. Country's first indigenous recombinant 'Streptokinase' 4. Developed fully indigenously the country's first combination vaccine of DTP + Hepatitis-B vaccines 	
Highlights of achievements	<ol style="list-style-type: none"> 1. Recipient of PADMA BHUSHAN – by Govt. of Indian in 2005 2. Several awards for entrepreneurial abilities and contribution to healthcare. 	
Education	BE (Electronics & Communication), MBA PG Diploma in Computer Sciences (Biblingen University, West Germany)	
Professional Association		
Membership	<ol style="list-style-type: none"> 1. Member of more than 20 national and international professional bodies. 2. Member of Working Group on Bio-business – National Biotech Policy 	

Dr. Albrecht Läufer

CEO and Cofounder, Corvay GmbH

Corvay provides expert consultancy in Life Sciences to customers in Germany and internationally, with a special focus on Asia. Corvay also is the management office of the Life Science Network Bioregion on behalf of the Ministry of Economics, Labour and Transport of Germany's State of Niedersachsen.



Dr. Laufer has 20 years of international management experience in the pharmaceutical and chemical industries in leading functions with Vakzine Projekt Management GmbH (cofounder and CEO), Solvay Pharmaceuticals (Regional Director for Asia, Middle East, Australia, Canada), Solvay Enzymes GmbH (CEO), Rütgerswerke AG.

He Studied biochemistry and chemistry in Tübingen, Basel, Tokyo, Braunschweig, doctorate in physical chemistry in Braunschweig.

Title: Transfer of novel academic research in vaccines into touchable results: new business models


Mr. Martin Gotting

Vice President, Intercell AG



Martin Götting is Vice President Marketing, Sales and Supply for Europe, Asia, Australia and ROW at Intercell AG, a fast growing biotech company that develops novel vaccines. He has a broad experience in the biotechnology and healthcare field. Since 1984 he works in numerous functions with increasing responsibility in the vaccines industry: For Behring Vaccines in the domestic German Marketing & Sales. For Chiron Vaccines he built up and headed the Logistics Department and became in 1999 Associate Director Commercial Operations. In this function he created an international distributor network for Chiron Vaccines for the commercialisation of vaccines. His main role in Intercell is to establish and maintain the commercialization of Intercell's novel JEV vaccine.

Title: The global future of vaccines: comeback of an established paradigm of medicine driven by innovation and entrepreneurship

Name Present Position & Affiliation	Dr. Raman Rao Vice President, Scientific & Medical Affairs, Shantha Biotechnics Ltd	
Professional Experience	<ol style="list-style-type: none"> 1. As head of clinical research and Medico-marketing, he is responsible for conducting pre-registration clinical trials for recombinant products, vaccines and diagnostic kits. 2. Designing protocols and other clinical research material. 	
Area of Research	Medicine, Clinical Microbiology with research in Fungal diseases	
Number of Publications	9	
Education	MBBS, MD, PGCBM	
Professional Association		
Membership	<ol style="list-style-type: none"> 1. Member Society of Indian and International human and animal mycologists. 2. Member Indian association of medical microbiologists. 	


Title: Biotechnology and Vaccines Industry

Name	Dr. S. Chandrasegaran
Present Position & Affiliation	Johns Hopkins Medical Institutions, Baltimore, USA
Professional Experience	Has been associated in various capacities with Johns Hopkins University since 1981.
On going projects	<p>RO1 GM077291 (PI: Chandrasegaran, S) NIH/NIGMS, \$190,000 The goal of this project is to develop zinc finger nucleases as reagents (ZFNs) for site-specific modification of mammalian cells including human cells.</p> <p>MCB 0718846 (PI Boeke, JD) (Co-PIs: S. Chandrasegaran & J. Bader) National Science Foundation, \$179,960 The major life goal of this project is to design a synthetic life form based on <i>Saccharomyces cerevisiae</i> that will be used to answer a wide variety of profound biological questions, including the minimum gene set compatible with free-living eukaryotic life and the fundamental requirements for genome and chromosome stability.</p> <p>H070382 (PI: Chandrasegaran, S) Maryland Stem Cell Commission, \$100,000 The major goal of this exploratory project is ZFN-mediated site specific insertion of foreign genes at a pre-determined locus of the human genome in stem cells to study their ectopic expression and its effect on cellular differentiation and cellular function.</p>
Number of Publications	28
Education	Ph.D in chemistry, Georgetown University, Washington, D.C.
Post Doc	Postdoctoral Fellow, Johns Hopkins University, Division of Biophysics, Department of Biochemistry, Bloomberg School of Public Health

Title: Targetted Engineering of the human genome

Session XI

Service Sectors (CROs, CMOs & Outsourcing)

Name	Prof. C. Channa Reddy	
Present Position & Affiliation	Director Emeritus, Huck Institutes of the Life Sciences, Penn. State University, USA	
Email	ccr1@psu.edu	
Phone	(814) 865-7696	
Fax	(814) 863-6140	
Professional Experience	For more than 15 years he has been in leading positions with the Huck Institutes of the Life Sciences, The Pennsylvania State University. He is a Distinguished Professor, College of Agricultural Sciences, and the Pennsylvania State University since 1991.	
Area of Research	Molecular Enzymology of Biological Oxidation Reactions	
Major Contributions	Gained international prominence as an expert in the molecular enzymology of glutathione requiring enzymes, increase knowledge of the molecular mechanisms involved in or responsible for regulating the biosynthesis of prostaglandins (PGs) and leukotrienes (LTs) by vitamin E and selenium.	
Number of Publications	124, Edited 2 books	
Highlights of achievements	1. Served on over 75 Ph.D. thesis committees during the last 25 years	
	2. More than 24 scholars have worked with him on Post-Doc assignments	
	3. Elected Fellow of the American Association for the Advancement of Science 1992.	
	4. Has successfully worked on projects (more than 30) funded by external agencies	
Education	Ph.D in Bio-chemistry (Indian Institute of Science, Bangalore)	
Post Doc	Bioorganic chemistry, Penn State University	
Professional Association		
Membership	Member of leading national and international professional societies	
Reviewer	<ol style="list-style-type: none"> 1. Member of the Advisory Editorial Board, Biochemical Journal, England (1994-present) 2. Member of the Editorial Board, Biofactors (1990- Present, Editor-in-Chief, Theresa Stadtman at NIH) 	

Mrs. Jumana Barnagarwala

Head of Healthcare Consulting & Principal Consultant, Datamonitor, India

Telephone: +91-40- 6672 9640

Mobile: +9966401563

Fax: +91-40-6677 01210

Email: jbarnagarwala@datamonitor.com



Jumana is a seasoned pharmaceutical sales and marketing professional with a 10 years of experience spanning various sales and marketing roles in two of the leading pharmaceutical companies in India – SmithKline Beecham (GSK) and AstraZeneca.

After her stint in the industry she has been involved in a number of customized research and strategic consulting projects as a freelance consultant, working in association with well known consulting and market research companies like Frost & Sullivan and Synovate respectively.

In her consulting role, from market due diligence for brand acquisition to assessing market potential for new products &/or indications and to concept testing of products &/or promotional material, she has been instrumental in the design and execution of a number of projects that have delivered useful insights to several multinational pharmaceutical organizations in India.

She has been heading the healthcare consulting vertical at Datamonitor, India for the last one year and has been involved in several strategic consulting assignments for large and medium-sized pharmaceutical, biotechnology, and medical devices companies in India as well as abroad.

Title: Biopharmaceutical Outsourcing: Opportunities and Challenges for Indian Companies

Dr. John M Hyde

Chairman & Founder, Hyde Engineering & Consulting, Inc., USA



John Hyde is Chairman and Founder of Hyde Engineering & Consulting, Inc., founded in 1993 and specializing in process systems engineering, compliance consulting and process, cleaning, sterilization and equipment validation for biopharmaceutical and pharmaceutical process systems. Since its inception, Hyde Engineering + Consulting has grown to 90+ engineers and scientists located in six offices in the United States and an international office in Hyderabad, India.


For nearly two years prior to the formation of Hyde Engineering & Consulting, Inc., John was Senior Project Engineer with Synergen, a biopharmaceutical research and manufacturing company located in Boulder, CO. His work at Synergen included design, start-up and validation of key process systems and the overall responsibility for the cleaning validation programs for the firm's large scale and clinical manufacturing facilities. From 1982 to 1992, John was Manager, Process Design with Seiberling Associates, Inc., an engineering firm specializing in the design and start-up of hygienic process systems and the application of CIP technology.

He has presented papers at numerous engineering conferences and short courses on topics including biopharmaceutical process systems design, automatic cleaning system design and implementation, and control system design for pharmaceutical processes, and he has published ten articles on these topics.

He, as a member of the PDA Subcommittee for Biopharmaceutical Cleaning Validation, contributed two chapters to a book on the subject, and he is completing a book manuscript on CIP technology.

John is a regular speaker on conferences presented by the Society of Bioprocessing Professionals (SBP), Pharmaconference, the Institute of Validation Technology (IVT), the International Society of Pharmaceutical Engineers (ISPE), the American Institute of Chemical Engineers (AIChE) and other professional societies. John has also provided CIP systems and cleaning validation training to FDA CBER personnel. He holds Bachelors degrees in Food Science and Business Administration, and a Masters degree in Food Engineering, all from the Ohio State University.

Title: Choosing a Contract Manufacturing Partner: Examining Biopharma Manufacturers Expectations for the Outsourcing of Production

Name	Dr. P. B. A. Nanda Kumar	
Present Position & Affiliation	Partner, Reedsmith Inc, USA	
Email	nkumar@reedsmith.com	
Phone	+1 215 241 7991	
Professional Experience	<ol style="list-style-type: none"> 1. Focuses on intellectual property and life sciences transactions. His patent prosecution concentrates primarily on biotechnology, medical diagnostics and pharmaceutical areas, and he also counsels clients regarding intellectual property licensing, due diligence and infringement matters. 2. Prior to entering the field of law, he held Senior Scientist research positions in industry and was a Post- Doctoral Research Fellow at The Center for Agricultural Molecular Biology, Rutgers University; The Biotechnology Center of Indian Agricultural Research Institute; and The Tata Energy Research Institute. 	
Area of Research	Genetics, biotechnology and molecular biology	
Publications	<ol style="list-style-type: none"> 1. Contributing Author, Black's Law Dictionary, Abridged Eighth Edition, 2005. 2. Co -authored numerous scientific publications and received several patents in the field of biotechnology 	
Education	Ph.D (University of Delhi)	
Professional Association		
	All State Courts, Pennsylvania All State Courts, New Jersey U.S. District Court, Eastern District of Pennsylvania U.S. District Court, District of New Jersey U.S. Patent and Trademark Office	

Title: Rushing to Outsource Pharmaceutical R&D to India? Consider a host Intellectual Property Issues

Session XIII

Nanotechnology for early diagnosis and therapy

Prof. P. Reddanna


School of Life Sciences, University of Hyderabad



Prof. Reddanna has been working in the area inflammation and cancer, specifically on the role of polyunsaturated fatty acids (PUFAs) and eicosanoids for the past 30 years. PUFAs such as arachidonic acid is mainly oxygenated by cyclooxygenase (COX) and lipoxygenase (LOX) pathways to generate eicosanoids such as prostaglandins, the mediators of inflammation & cancer and leukotrienes, the mediators of allergy and asthma. While working on basic research to understand the role of eicosanoids in reproduction, he also studied their role in inflammation and cancer, which helped him to interact with the leading pharma and biotech companies in the country. Some of the companies include Dr. Reddy's Laboratories, Shantha Biotechnics, Indian Immunologicals, Surya Pharmaceuticals, Medgene Biotech, Laila Impex, Dabur Research Foundation, etc. Currently he has ongoing industrial research projects sponsored by Natco Pharma, Hyderabad; ABL Biotechnologies, Chennai, Celestial Laboratories, Hyderabad and Onconova Therapeutics, USA.

The significant work done by Prof. P. Reddanna is on Chronic myeloid leukemia (CML) a cancer of blood cells. Prof. P. Reddanna, with financial support from Natco Pharma, has developed potent drug candidates for the treatment of chronic myeloid leukemia. Further his group has shown the use of COX-2 inhibitors (Asprin like drugs) in overcoming drug resistance in CML and other cancers. These findings open up a novel approach in the treatment of cancer patients with Multidrug resistance. In addition he developed high throughput screening (HTS) assays for screening compound libraries and identified anti-inflammatory and anticancer drug candidates. His group has also isolated and identified natural products like C-Phycocyanin, Betanin, Oxylipids etc. with anticancer properties against CML. Currently Prof. Reddanna is involved in the screening and analysis of various nanoparticles for their inflammatory responses and identifying the ideal nanoscaffolds suitable for the optimal growth of hepatocytes.

Prof P. Reddanna, working at University of Hyderabad since 1990, obtained Masters (1976), Doctorate Ph.D. (1979) and worked as faculty (1982-90) at Sri Venkateswara University, Tirupati. He did post doctoral research at Penn Sate University, USA (1984-87) and was visiting faculty at Johns Hopkins University, USA and Humboldt University, Berlin, Germany. He has published more than 150 research articles and guided 30 students for Ph.D. Prof. P. Reddanna is the recipient of the Rockefeller Foundation Biotechnology Career Award, the Chemtech Foundation Pharma-Bio Award", The Royan International Foundation, Iran "Best Research Project Award" and the FAPCCI "outstanding scientist for the benefit of Industry" award.

Name	Dr. Sundara Ramaprabhu	
Present Position & Affiliation	Professor, Alternative Energy and Nanotechnology Laboratory (AENL) Nano Functional Materials Technology Centre (NFMTC) Department of Physics; Indian Institute of Technology Madras	
Email	ramp@iitm.ac.in, ramp@physics.iitm.ac.in	
Professional Experience	Professional affiliation to: Alaxander von Humboldt-Stiftung (AvH) Fellow, Germany; DAAD Fellow, Germany; Visiting Fellow to Germany by BMBF & DFG German Science Foundations & Visiting Fellow to South Korea	
Area of Research	Hydrogen Energy Technology, Nanotechnology, Fuel Cell Technology	
Number of Publications	140, presented papers in 80 conferences	
Patents	10	
Highlights of achievements	1. Developed 5 technologies	
	2. Completed 16 projects worth Rs.2.11 cr; there are 11 ongoing projects worth Rs.25.23 cr. (DST, DRDO, NMRL, RCI, DRDE, DMSRDE, MNRE, MHRD, NRB, VSSC, US Air force)	
Professional Association		
Membership	<ol style="list-style-type: none"> 1. Member of American Chemical Society; Member in International Association of Hydrogen Energy 2. Member on scientific advisory board of <ul style="list-style-type: none"> • 2nd International Conference on “Advanced Nano Materials”, ANM 2008; June 22nd -25th 2008, Aveiro, Portugal • International Conference on “Hydrogen and Hydrogen Storage: Methods and Materials”, IISc, Bangalore 2009, India (Jan 3- 6, 2009) 	
Editorial Board	NanoTrends and Nanotechnology; International Journal of Biosciences and Technology; Carbon- Science and Technology	
Reviewer	6 National and international journals	

Title: Nanomaterials and their energy and nanomedicine applications

Name

Present position & Affiliation

Prof. Devraj RambhauAdvisor, Novel Drug Delivery Division
Natco Research Centre,
Natco Pharma Limited, Hyderabad.

Email

drambhau@yahoo.co.in

Phone

+ 91 –40 –23812583

Fax

+ 91 –40 –23710578

Professional Experience

- 1 32 years Teaching/Research experience. Served as professor for 21 years at University. College of Pharmaceutical Sciences. Was Dean, Principal/ Head for more than 10 years.
- 2 Worked as Director – Technical services for Pulse pharma for 2 ½ years.

Area of Research

- 1 Novel drug delivery systems including liposomes, niosomes, micellar systems, lipid microspheres and lipid nanoparticles.
- 2 Drug targeting
- 3 Chronopharmacokinetics
- 4 Bioavailability studies on pharmaceutical disperse systems using human subjects.
- 5 Application of zeta potential in the stability predictions of various pharmaceutical disperse systems.

Major Contributions

- 1 First in the country developed nanotechnology based drug delivery platform.
- 2 Pursued research on Chronopharmacokinetics for 1 ½ decades and applied it in the development of temporal drug delivery systems.
- 3 Designed zeta potential measuring instrument indigenously, applied concept of zetapotential in the stability prediction of pharmaceutical disperse systems.

No. of Publications

- 1 126 publications in peer-reviewed national / international journals.
- 2 68 reports / conferences abstracts.
- 3 42 symposium/ seminars, panel discussions/ workshop presentations as resource person
- 4 25 Ph.D produced, 3 in pipeline

Patents

6 patents in nanotechnology formulation development.

Highlights of achievements

- 1 Was In-charge vice chancellor, Kakatiya university.
- 2 Was recipient of Best Teacher award of state of Andhra Pradesh.
- 3 Was recipient of Welcome Foundation, U.K, American Toiletries and Cosmetics awards and several other Research awards.
- 4 Was visiting Professor to Freie University, Berlin, Germany and school of pharmacy of Otago University, New Zealand.

Education

B. Pharm, Nagpur University

Post Doc.

FISC France

Ph.D

Ph.D in pharmaceutical sciences Nagpur University

MSc

M.Pharm (Pharma-Technology), Nagpur University

Title: Multifunctional nanocarriers

Dr. M. Rami Reddy

Co-founder and chairman of RR Labs Inc., California, USA, and Rational Labs Pvt. Limited Hyderabad



Dr. Rami Reddy Mutyala (Dr. Reddy) is a co-founder and chairman of RR Labs Inc., based in San Diego, California, USA, and Rational Labs Pvt. Limited, based in Hyderabad. The primary focus of these companies is to accelerate drug discovery and development in several disease areas using Medicinal chemistry, Bioinformatics, Cheminformatics and novel Computer Aided Drug Discovery (CADD) approaches.

And also, Dr. Reddy is a Scientific Consultant for Computer Aided Drug Discovery, Structural Biology and Informatics at Metabasis Therapeutics, Inc., La Jolla, California, USA, where his primary focus is to contribute to the development of novel drugs for important human diseases.

An alumnus of the University of Hyderabad, Dr. Reddy is one of the world leaders in the research area of computer aided drug discovery and has an extensive pharmaceutical industry experience in developing CADD technology and its application for the discovery of drugs for human diseases. He is an author of about 100 scientific publications as well as inventor on four patents. He has been an invited speaker at several national and international conferences and pharmaceutical industries. He has developed several computer aided drug design programs and has edited two Rational Drug Design text books and a third textbook is in preparation. He is also an executive editor of "Current Pharmaceutical Design" Journal and edited two special issues on Computer Aided Drug Design. He has organized five symposiums on computational aspects of Rational Drug Design (1997-2007) as part of the American Chemical Society National meetings.

For the last 5 years, Dr. Reddy and Dr. Mark Erion in consultation with Dr. U. C. Singh (AM Technologies) have developed highly accurate Free Energy Perturbation (FEP)-based CADD software, which produces more-reliable predictions on which to base drug-design decisions, thereby reducing the time and cost it takes to find suitable drug candidates to evaluate in human clinical trials.

Prior to Metabasis Therapeutics, Dr. Reddy was at Agouron Pharmaceuticals, La Jolla (later acquired by Pfizer) and he was a member of the AIDS and Cancer projects and Computer Aided Drug Design and Bioinformatics efforts at Agouron contributed significantly for the discovery of several clinical candidates for cancer and one FDA approved drug for AIDS (Viracept). In 1995, Agouron Pharmaceuticals obtained FDA approval for Viracept to treat AIDS patients by using it as part of the cocktail drugs.

Title: Use of Computer Aided Drug Design Methods and Structural Bio-Informatics in the Discovery of a New Class of Clinical Candidates for Diabetes

Dr. Chandra U. Singh


Founder, President and CEO, Trinity Laboratories Inc.




Prior to founding Trinity Laboratories Inc. in 2006, Dr. Chandra Singh founded Azaya Therapeutics Inc. in 2002 and is the largest share holder of the company. Prior to that, Dr. Singh co-founded BioNumerik Pharmaceuticals in 1992, serving on the Board of Directors and as Vice President of Research and Development. Prior to BioNumerik, Dr. Singh co-founded Immunopharmaceutics in San Diego, California in 1989 and was scientific advisor to the company until 1992. Immunopharmaceutics was sold to Texas Biotechnology Corporation in 1994. Dr. Singh was an Assistant Professor at Scripps Clinic and Research Foundation in La Jolla, California from 1986 to 1992. At Scripps, Dr. Singh worked intensively on the development and application of molecular modeling and simulation for drug design using CRAY supercomputer. Dr. Singh received his Ph.D. in Physical Chemistry from Madurai Kamaraj University in 1976. Dr. Singh was a post-doctoral fellow at the School of Pharmacy at the University of California-San Francisco, where he developed AMBER, the world-renowned computer molecular modeling software for rational drug design and molecular simulation.


Title: Stable Solid Nanoparticle Delivery System for Cancer Drugs

Session XV
Stem Cell Research Scenario in India


Name	Dr. D. Balasubramaniam	
Present Position & Affiliation	Director of Research, L. V. Prasad Eye Institute, Hyderabad. Also Visiting Professor, University of New South Wales, Sydney, Australia, Senior Fellow, University of Melbourne, Australia, and Adjunct Professor, BITS Pilani, India	
Email	dbala@lvpei.org, dbala@operamail.com,	
Phone	+91-40-2354 3652	
Fax	2354 8271	
Professional Experience	More than 40 years of research and teaching experience with the Centre for Cellular & Molecular Biology (Hyderabad), University of Hyderabad, and Indian Institute of Technology (IIT), Kanpur.	
Area of Research	Molecular and Cellular Approaches to Understand and Treat Diseases of the Eye	
Major Contributions	1. Work in the area of Public Understanding of Science, through popular science newspaper columns, radio and TV programs; published over 300 popular articles and 6 books.	
	2. working with governments and agencies on issues of science and technology; Chairman- Biotechnology Advisory Council, Govt. of Andhra Pradesh	
Number of Publications	150 research papers and 2 books	
Highlights of achievements	1. Recipient of Padma Shri": National honour by the President of India, 2002	
	2. Received "Chevalier de l'Ordre National de Merite": National honour by the President of France, 2002.	
	3. Received 6 other national awards	
Education	Ph. D. Chemistry, Columbia University, New York, USA, 1965;	
Post Doc	Postdoctoral Fellow: Univ. Minnesota Medical School, 1965-66.	
Professional Association		
Membership	Member- Board: Inst. of Life Sci., Hyderabad; Member- Board of Directors: VIMTA labs, Hyderabad.	

Name	Dr. Alka Sharma	
Present Position & Affiliation	Joint Director, Department of Biotechnology, Ministry of Science & Technology, Government of India	
Email	alka@dbt.nic.in; alkadbt@yahoo.co.in	
Phone	24363699	
Fax	24362884	
Professional Experience	Research experience on nearly 10 years with the Deptt. Of Biotechnology, Govt. of India, also a member of policy making bodies.	
Area of Research	Stem Cells	
Major Contributions	1. Generated and implemented clinical and basic research programmes on various aspects of stem cells.	
	2. Initiated and implemented programmes in the area of Bioengineering, Genomics, clinical proteomics and RNAi.	
	3. Established a “CMC-DBT Centre for Stem Cell Research” at CMC, Vellore to carry out both basic, clinical and translational research.	
	4. As a member Secretary of “National Bioethics Committee” formulated ethical policy document on “Human Genome, Genetic Research and Services”	
	5. As a member Secretary, finalized “Guidelines for stem cell research” jointly with ICMR, New Delhi	
Number of Publications	20	
Patents	International - 17 National - 4	
Highlights of achievements	As a team member, three technologies have been developed. One technology has been transferred to an entrepreneur on non-exclusive basis.	
Education	Ph.D (Banaras Hindu University (BHU), Varanasi	
Professional Association		
Membership	Association of Microbiologists of India	


Title: Stem Cell Research - A National Scenario

Name	Dr. Geeta K Vemuganti	
Present Position & Affiliation	Head, Ophthalmic Pathology Service & Head, Stem Cell Laboratory LVPEI, Hyderabad	
Email	geeta@lvpei.org; gkvemuganti@yahoo.com	
Phone	93999- 86909	
Fax	-	
Professional Experience	15 years in the field of pathology and 7 years in Stem Cell research	
Area of Research	Ocular Infections, Ocular Tumors, Stem Cells and Translational Research, Cancer Biology	
Major Contributions	Established and popularized Ocular Pathology, Initiated the first translational Stem Cell Therapy in India and the largest series in the world – facilitated ocular cell therapy for more than 530 cases.	
Number of Publications	128 (Papers: 104 Abstracts: 19; Book chapter: 5)	
Highlights of achievements	1. Established Cell cultures of limbus and conjunctiva on human amniotic membrane for clinical Transplantation and novel concept of Co-culture and Presence of stromal cells in limbus.	
	2. Established Stromal cells from unstimulated diagnostic marrow tap, documenting the plasticity	
	3. Received 15 grants from funding agency, worth Rs.10 cr from various agencies	
	4. Received 14 awards for contributions in ocular pathology and stem cell research	
Education	MBBS, DCP, MD, DNB, FNAMS	
Post Doc	Short fellowship in Ocular Pathology	
Professional Association		
Membership	International : 4	
	National : 15	
Reviewer	International Journals : 7	
	National : 8	

Title: Step by Step progress towards Tissue Engineering of Cornea

Name	Dr. Sujata Mohanty	
Present Position & Affiliation	Assistant Professor, Stem Cell Facility, All India Institute of Medical Sciences, New Delhi	
Email	sujmohanty@yahoo.co.in	
Phone	26593085 (Ext. 3085)	
Fax	26588641; 26588663	
Professional Experience	Joined AIIMS in 1989 and progressed to the post of scientist in 1990. In 2005 she moved to the present position of Assistant professor in the Stem Cell Facility.	
Area of Research	Stem cell research	
Number of Publications	35	
Education	Ph.D, M.sc	
Professional Association		
Membership	<ol style="list-style-type: none"> 1. International Society for Stem Cell Research 2. The Cytometry Society 	

Title: Stem Cell Research at AIIMS

<p>Name</p> <p>Present Position & Affiliation</p>	<p>Dr. Deepa Bhartiya</p> <p>Assistant Director and Head, Stem Cell Biology Department, NIRRH, Mumbai</p> 
<p>Email</p>	<p>deepa_bhartiya@yahoo.com</p>
<p>Professional Experience</p>	<p>Derivation of ES cell lines from spare embryos and also by SCNT and Parthenogenesis and Differentiation of ES cells.</p>
<p>Area of Research</p>	<p>Embryonic stem cells</p>

Title: Research Initiatives to Realize Clinical Potential of Embryonic Stem Cells

(Session XVII)
Manpower Challenges in Biotechnology

Prof. V. S. Rao

Director, Birla Institute of Technology and Science, Hyderabad



An alumnus of BITS-Pilani, Prof. V S Rao is currently the Director of BITS-Pilani, Hyderabad Campus. He graduated from studentship in BITS to the present position and has been with the Institute for the last 32 years. His previous position was Dy. Director, (Off-campus Programmes) & Dean, Practice School Division, responsible for Practice School and Work Integrated Learning Programmes at BITS.

He is a Ph.D from BITS, and Master of Science, besides having been awarded a certificate on Educational Economics and Educational Research, by the University of Bielfeld, Germany in 1998.


He is a highly rated educationist with specialization in Assessment of Training Needs, Institution-Industry interface design, Curriculum Development, development of Practice School! Off-campus infrastructure, Project Management and has equally specialized in Organic Chemistry, Drug Design and Synthesis and Green Chemistry besides having established a new campus in the Higher Education sector.

He has attended various conferences! seminars and has organized various conferences a few among which are (1) National Symposium on "Challenges in Drug Discovery Research: Networking Opportunities between Academia & Industries" at BITS in April, 2006, (2) National Seminar on "University-Industry linkages at BITS in November, 1995, (3) National Seminar on "co-operation among University, research and Industrial Enterprises" in April, 1994, etc. At the invitation from DSE, German Foundation for International Development, he has attended a four month training programme on Educational Economics and Educational Research.

A scientist by profession, he has a lot of publications to his credit, specially in the areas of Synthetic Communications, Natural Product Research, Green Chemistry etc. and has seamless research and project experience.

He is a member of (1) World Association for Cooperative Education, Inc., Boston, USA, (2) Senate, BITS-Pilani, (3) Board of Governors, BITS, Pilani, besides a coordinator of Internal Quality Assurance Cell (IQAC) for NAAC, BITS-Pilani and expert member on the research council of North East Institute of Science & Technology, 10'hat.

He has widely traveled across the world, like Kathmandu University in Nepal, UNESCO, Paris, Deutsche Stiftung fur internationale Entwicklung (DSE) Germany, various educational conferences ,in the US, INSEAD, France, to name a few. His interest lies in all realms of education and research and guiding the young generation on educational issues.


Name	Dr. Arjula R. Reddy	
Present Position & Affiliation	Professor, University of Hyderabad and Vice Chancellor, Yogi Vemana University, Kadapa, 516003 (A.P)	
Email	arjulsl@uohyd.ernet.in arjulsl@yahoo.com	
Professional Experience	Scientist with advanced research and teaching experience of 30 years, has guided more than 50 research scholars.	
Area of Research	Genetics and Biotechnology	
Major Contributions	<ol style="list-style-type: none"> 1. His laboratory, has been active in sequencing a huge number of rice genes and making them available in public domain. 2. Played an important role in establishing several National and International collaborations and developing advanced research programs using cutting edge technologies such as functional genomics, association genetics, genetic engineering etc. 	
Number of Publications	12 (in last five years)	
Highlights of achievements	<ol style="list-style-type: none"> 1. Has attracted funding from highly reputed international organizations such as the Rockefeller Foundation, European Union, CGIAR organizations besides national organizations such as Dept. of Biotechnology, UGC, ICAR etc to do research on drought and rice. 2. He received several awards and honors, including fellowship of leading international institutes. 	
Education	Ph.D in Genetics from Osmania University	
Professional Association		
Membership	Committees of Biotechnology, Govt.of India	
	National Task Force on Agricultural Biotechnology, Member, Review committee on Genetic Recombination, Various committees of the University of Hyderabad	

Mr. Suresh Narayanan
Chief Editor, Biospectrum, Bangalore

E-Mail: sureshn@cybermedia.co.in, nnsuresh@gmail.com

Tel: +91 80 22861511 Fax: +91 80 22862971

Mobile: +91 98 455 18573



Narayanan Suresh is the Group Editor(Senior VP) of BioSpectrum. Published by CyberMedia since March 2003, BioSpectrum is India's first and only Biotechnology business magazine. Suresh is also the editor of the Asia edition of BioSpectrum, published from Singapore for a global audience.


He has been tracking the growth and strides made by Indian technology sector for 22 years, first for The Times of India and later for CyberMedia Publications. Suresh is also a consulting editor for CyberMedia's flagship IT magazine, DATAQUEST. Suresh is sought after as an analyst of India's technology business trends and interacts with a cross section of stakeholders in the Indian biotech sector.

Suresh started his career as The Times of India's first Science and Technology Correspondent in 1986 and has written extensively on major developments in nuclear, space, energy, agriculture, biotech, pharma and information technology sector.

Suresh is also a Life Member of one of India's leading consumer organizations, Consumer Unity and Trust Society (CUTS), which is headquartered in Jaipur, Rajasthan and has operations in Delhi, London and many African countries.

He covered various developments in the patents sector. It was his report about the patenting of turmeric by researchers in the US in the Times of India in 1995 which alerted the Indian governments which got it revoked from the US Patent Office after a two-year legal proceedings. Suresh has exposed various other major developments in the patents segment in the last decade. He has presented many papers on the issue in the United Nations, UNEP and other institutions.

He is a Masters in Physics from University of Hyderabad. Suresh has also got a Post-Graduate Diploma in Social Journalism, from The Times Center for Media Studies, New Delhi

<p>Name</p> <p>Present Position & Affiliation</p>	<p>Dr. Shrikumar Suryanarayanan</p> <p>Director General, ABLE, Bangalore</p>	
<p>Professional Experience</p>	<p>Currently the Director-General of the Association of Biotechnology Led Enterprises of India (ABLE), headquartered at Bangalore. He was formerly the President of Research and Development of Biocon limited.</p>	
<p>Area of Research</p>	<p>Bioprocess technology and Biofuels; Diabetes and Inflammation</p>	
<p>Major Contributions</p>	<p>At Biocon, responsible for development of:</p> <ol style="list-style-type: none"> 1. many processes for industrial enzyme production, the design and construction of a novel bioreactor for Solid State Fermentation, 2. pharmaceutical small molecules by fermentation and synthetic chemistry, 3. A Biotherapeutics program which included injected and oral insulin, several recombinant therapeutics and monoclonal antibodies. <p>Have been contributing his experience to the development of Biotechnology and Biosciences research & education in India.</p>	
<p>Education</p>	<p>B.tech, M.tech</p>	
<p>Professional Association</p>		
	<ol style="list-style-type: none"> 1. Associated with leading institutions in India and Sweden 2. Technical Advisor to the Department of Biotechnology, Govt of India 3. Member of the Scientific board for Biocon Limited, a leading biotechnology company 	

Mr Ravi C Dasgupta

Group HR Head, Biocon, Bangalore



Ravi C Dasgupta is the Head - Group HR at Biocon Limited, Bangalore, one of India's leading bio-pharmaceuticals companies with a therapeutic focus in the areas of diabetes, oncology and cardiovascular disease. He joined Biocon in January 2007 and is responsible for corporate human resources as well as mentoring the HR teams of our group companies.

Ravi completed his B.Sc specialising in Biochemistry from St. Xaviers College Ahmedabad in 1985 and his PGD(PM&IR) from XLRI in 1988. Thereafter he completed his LLB General Degree while working.

Ravi has two decades of experience in Human Resources and has worked across sectors like Paints, Engineering and Finance in the initial part of his career before moving to the Pharmaceutical industry in 1995. He has handled a specialist HRD role in a Pharmaceutical Multinational looking after Recruitment, Training , Performance Management , Compensation and Job Evaluation before taking on the role of HR Director in another Pharmaceutical MNC in the year 2000.

He has demonstrated competence across the spectrum of HR and is an accomplished soft skills trainer who has facilitated training workshops for employees at all levels between factory workmen and medical representatives to Regional Directors. He has developed competency based HR systems for recruitment, selection and training. Further, he has developed and run about 20 assessment / selection centers for middle and senior managers.

Dr. S P Vasireddi

Founder, Chairman & Managing Director, Vimta Labs Limited, India

Dr. Vasireddi founded Vimtas Labs Limited in 1984 with a long-term objective of providing Contract Research and Testing services to national and international markets. As the Chairman & Managing Director of the company, he leads a scientific community of over 650 professionals in various disciplines such as Clinical & Drug development.



Dr. Vasireddi was presented with the outstanding CRO Management Award for the year 2006 by the Indian Drugs Manufacturers' Association. Under his leadership, VIMTA has bagged awards for outstanding exports in the business services category from the Federation of Indian Export Organizations (FIEO) for three consecutive years i.e. 2003 to 2005.

Dr Vasireddi is the founder Chairman of the Association of Contract Research Organizations (ACRO), India. He is also the Asian and Pacific Regional Representative for the World Association of Industrial and Technological Research Organization's (WAITRO) Executive Committee.


TRACK II

(Session II)

Crop Biotechnology: Scope and Challenges

Prof. VL Chopra

Member, Planning Commission, New Delhi



Prof. Virendra Lal Chopra obtained his Associateship of Indian Agricultural Research Institute (IARI) in 1957 and Ph.D. from the University of Edinburgh in 1987. Prof. Chopra has been a researcher, administrator and a teacher, He has made significant contributions in generation and management of genetic variability and development of products of commercial value in the form of released crop varieties. Using biotechnologies! approaches, Prof. V.L. Chopra, along with his colleagues, has developed varieties of mustard, which have resulted in higher yields of seed and oil. His studies on reproductive control of Brassica has led to the development of diversified cytoplasmic male sterile lines and their restorers, thus, laying foundation for production of hybrids of Indian Mustard, Brassica juncea.


Prof. V.L. Chopra has served Indian Agricultural Research Institute, New Delhi (IARI) for more than four decades in various capacities. He was Professor of Genetics from 1970 to 1974 and Head of the Division of Genetics from 1972 to 1980, In 1985 he took over as the founder Project Director of The Biotechnology Centre of IARI and was responsible for establishing it as an Institution of international fame. As an FAO's Consultant to the Govt. of Vietnam, he helped in establishing the Institute of Agricultural Genetics in Vietnam. In 1992 Prof. Chopra took over as Director General of Indian Council of Agricultural Research and Secretary, Department of Agricultural Research and Education. In recognition of his research contributions Prof. Chopra was awarded the National Professorship, Dr. B.P. Pal Chair of ICAR in 1994. He has been Chancellor of Central Agricultural University, Imphal and member of Science Council of Consultative Group of International Agricultural Research.

Prof. Chopra has guided a score of Ph.D. students and has been honoured by a number of science academies and societies in India and abroad. He is a Fellow of the Indian National Science Academy, the Third World Academy of Science, European Academy of Science, Arts and Humanities and President of the National Academy of Agricultural Sciences. He served as President of the International Genetics Federation, Indian Society of Genetics and Plant-Breeding, Society for Oilseed Research and Society for Advancement of Breeding Research in Asia and Oceania. Prof. Chopra has been Vice-Chairman of the Boards of the International Board for Plant Genetic Resources and International Crop Research Institute for the Semi-Arid Tropics and a member of the Boards of CIMMYT and IRRI. His role in the organization of the XV International Congress of Genetics in 1983 was widely appreciated.

Prof. V.L. Chopra is recipient of a number of national and international awards. He was awarded the Padma Bhushan in 1985. He has authored nine books on genetics and biotechnology and published more than 150 research papers in prestigious journals.

Name Present Position & Affiliation	Prof. Marc Van Montagu Founder and Chairman, Institute of Plant Biotechnology for Developing Countries, Belgium	
Email	mamon@psb.ugent.be	
Professional Experience	He is professor emeritus, director of the Institute Plant Biotechnology for Developing Countries, Ghent University, and adviser to the Flanders Inter University Institute of Biotechnology.	
Area of Research	Plant biotechnology	
Major Contributions	<ol style="list-style-type: none"> 1. One of the discoverers of the Ti-plasmid and gene transfer mechanism between <i>Agrobacterium tumefaciens</i> and plants. 2. Pioneered the construction of transgenic crops (tobacco, rape seeds, corn) resistant to insect pests (BT-plants) and tolerant to novel herbicides. 	
Highlights of achievements	Recipient of: <ol style="list-style-type: none"> 1. Title of Baron (1990) 2. Recipient of Rank Prize for Nutrition (The United Kingdom) – 1987; 3. IBM-Europe Prize (France) – 1988; 4. The Charles Leopold Mayer Prize (Academy of Sciences, France) – 1990; t 5. The five yearly prize of the Belgian national fund for scientific research) – 1990; 6. The Japan Prize (Japan) 	
Professional Association		
Membership	<ol style="list-style-type: none"> 1. President of the European Federation Biotechnology and the Public Research Regulation Initiative. 	
	Member of <ol style="list-style-type: none"> 2. The Belgian Royal Academy of Sciences; NAS, USA (1986); 3. Academia Europea; Agricultural Academy, Russia; 4. Academy of Engineering, Sweden; Agricultural Academy, France; 5. Royal Academy of Overseas Sciences; and the Italian Academy of Sciences detta dei XL, and TWAS (Agriculture Sciences 2001). 	

Title: Society, Industry and the Environment need a Global Investment in Plant Biotechnology

Name	Prof. Heinz Saedler	
Present Position & Affiliation	Director, Max-Planck Institute, Koln, Germany	
Professional Experience	35 years of teaching and research experience	
Area of Research	Transposable elements in plants, flower development and evolution, mechanisms of evolution of plants	
Highlights of achievements	Recipient of:	
	1. " Otto Bayer Preis" (1985)	
	2. "Tracy and Ruth Storer Lectureship in the Life Science", University of California, Davis (1990)	
	3. Hill Visiting Professorship in Plant Biology, University of Minnesota, St. Paul (1993)	
	4. Wilhelm Exner Medaille, Wien (2000)	
Education	Ph.D. in Genetics (1967) - Cologne	
	Postdoctoral Fellow: (1969-70) Department of Biological Sciences, Stanford University	
Professional Association		
Membership	A member of European Molecular Biology Organization, " Leopoldina" German Academy of Science and other international associations.	

Title: Plant Biodiversity and the Survival of Humans

Dr. Roberto Tuberosa

Department of Agroenvironmental Sciences and Technology, University of Bologna, Italy



Roberto Tuberosa earned a Ph.D. in Plant Breeding at the University of Minnesota, USA. He is currently full Professor in “*Biotechnology applied to plant breeding*” at the Dept. of Agroenvironmental Sci. & Technology, University of Bologna, Italy. His research activities focus on: Marker-assisted techniques in wheat, maize and barley to identify Quantitative Trait Loci (QTL) for yield, drought tolerance and disease resistance; positional cloning of QTL in maize and wheat; TILLING in barley and EcoTILLING in durum wheat. He collaborates actively with seed companies to apply genomics and marker-assisted selection to breeding projects.

R. Tuberosa has published over 90 papers in peer-reviewed journals and volumes. He is an active member of ASA, EUCARPIA, FESPB, IAPTC and SEB. He is member of the Editorial Board of: *Acta Agronomica Sinica*, *Journal of Plant Genomics*, *Maydica*, *Molecular Breeding*, *Plant Biotech Journal*, *Plant Breeding*, *Plant Genetic Resources*.

Additionally, R. Tuberosa is:


- Italian Scientific representative in the Generation Challenge Program
- Honorary scientist of the Rural Development Administration of the Republic of South Korea
- Chair of the Scientific Committee of the Italian platform “Plants for the Future”
- Member of the Board of the Maize-Sorghum EUCARPIA section
- Member of the Program Board of the Plant Genomics European Meetings
- Member of the Scientific Board of Genoplante

He has chaired sessions and presented invited talks at more than 30 international Congresses. He has actively participated to 27 research projects and is presently involved in 11 research projects funded by public and private agencies. He has been involved in the organization of 11 international workshops/ congresses and annually organizes a workshop on “*QTL cloning*” at the annual Plant & Animal Genome congress held in San Diego.

Title: Leveraging genomics to improve cereal production in a changing climate: results and challenges ahead

(Session IV)


Food Technology: Human Health and safety

<p>Name</p> <p>Present Position & Affiliation</p>	<p>Dr. B. Sesikeran Director, National Institute of Nutrition (NIN), Hyderabad</p> 
<p>Email</p>	<p>sesikeran@hotmail.com</p>
<p>Professional Experience</p>	<p>Have been working in NIN in various capacities since 1977.</p>
<p>Area of Research</p>	<p>Nutritional Pathology, Toxicology, Oncology; sub-areas are Diet and cancer, Nutrition and Apoptosis</p>
<p>Major Contributions</p>	
<p>Number of Publications</p>	<p>48 and One chapter in Textbook of Dermatology</p>
<p>Highlights of achievements</p>	<p>Recipient of 5 awards</p>
<p>Education</p>	<p>MBBS, MD (Pathology)</p>

Title: Biosafety Protocols of GMO's

Dr. G. Sarwar Gilani


*Senior Research Scientist, Nutrition Research Division, Health Canada,
Government of Canada*



Dr. Gilani, after working as a Post-Doctorate Fellow at the University of Alberta and as a Research Adviser for the Rapeseed Association of Canada, joined the scientific staff of the Bureau of Nutritional Sciences of Health Canada, Government of Canada in 1977. Since that time, he has been working as a Research Scientist in the Nutrition Research Division in Ottawa, in the area of safety, nutritional quality and health aspects of dietary proteins and associated minor bioactive components such as phytoestrogens and trypsin inhibitors. Dr. Gilani is the author of more than 100 research papers and book chapters. He is also the senior co-editor of the AOCS (American Oil Chemists Society) book on Phytoestrogens and Health published in 2002.

In 2002, Dr. Gilani was a recipient of the Commemorative Medal for the Queens' Golden Jubilee for his significant contributions to Canadians and the international community. In 2004, as a Distinguished Scientist, Dr. Gilani received the Deputy Minister's Award for Excellence in Science for longstanding and continuing contribution to maintaining and improving the health of Canadians and enhancing Health Canada's science base and credibility. Dr. Gilani has been a member of the 2002 WHO/FAO Expert Consultation on Protein and Amino Acid Requirements, and has acted as an advisor FAO/WHO's expert committees on protein quality assessment, and to the FASEB Expert Consultation on assessment of Nutritional Requirements of Infant Formulas.

Title: Role of Biotechnology in Increasing Safe Bioactive Peptides in Crops for Potential Promotion of Human Health

Name	Erick Boy-Gallego	
Present Position & Affiliation	Nutrition coordinator, Global Research Program, HarvestPlus, USA	
Email	e.boy@cgiar.org	
Phone	Office: (613) 782-6808; Mobile: (613) 853-9592	
Professional Experience	A medical doctor, with a strong background in epidemiology. For the last 15 years, has been involved in international programs at INCAP/PAHO, the Micronutrient Initiative, and IFPRI and collaborating with WHO, UNICEF, PAHO, international NGOs, and local development partners, especially in Latin American region.	
Area of Research	Nutrition and public health	
Major Contributions	1. Played a pivotal role in the implementation of Nicaragua's sugar fortification program and the development of its integrated nutrition interventions surveillance system (SIVIN);	
	2. Brokering key information that enabled buy-in from the private food industry in Dominican Republic to adhere to universal salt iodization;	
	3. Training of Panama's and El Salvador's primary health care physicians to detect goiter.	
	4. Championed the uptake of home fortification of complementary foods to alleviate anemia among children under 2 years in Bolivia, Guatemala, Nicaragua, Haiti, Ecuador, Peru, and Argentina.	
Number of Publications	12 (Related to public health nutrition and health on micronutrient topics)	
Highlights of achievements	At the Institute of Nutrition of Central America and Panama (INCAP/PAHO) headquarters in Guatemala, conducted research in maternal/perinatal health and nutrition	
	Prompted novel applied micronutrient research initiatives in human nutrition and food technology and monitored projects funded by the MI in Latin America, South Asia & Eastern-Southern Africa.	
Education	<ol style="list-style-type: none"> 1. Medical degree from the University of San Carlos, Guatemala, 1987. 2. Master's (1992) and doctoral (2005) degrees in nutrition from the University of California-Davis 	
Professional Association		
Membership	Member of international health nutrition scientific committees and reviewer for several international peer reviewed nutrition journals.	

Title: Agriculture Is The (Unrecognized) Primary Tool for Better Human Health

Session VI

Seed Technology: An important Industry in developing Countries

Dr. P. Vidyasagar

Chairman & Managing Director, Vibha Agrotech Ltd, Hyderabad

Mr. Vidyasagar Parchuri, Chairman and Managing Director of the Vibha seed Group, is an ICRISAT researcher turned entrepreneur, who established Vibha seed Group in 1995 with a vision of empowering Indian farmers to provide superior quality seeds of agri-horticultural crops.




He is MS in Technology of Crop Protection from University of Reading, England. He holds a rich research experience of 25 years, with 12 years in ICRISAT and 14 years in Indian Seed Industry and an exposure to world class technologies. He has been trained from renowned institutes like ICI Jealot Hill Research station, Shell Sittingborne Research Center, Overseas Pesticide Research Center, Sillwood Park, Cambridge Plant Breeding Institute in U.K. and in several management courses conducted by Indian Institute of Management (IIM).


Mr.Vidyasagar is a techno-commercial entrepreneur with a strong belief in science. His dynamic leadership skills has evolved Vibha seed group into a thorough Research & Development (R&D)-based premier private research organization for crop genetics and hybrid seeds. Through the twelve years of growth and success, the group now leads the Indian seed market with its R&D, production and distribution of quality seeds of 154 products in 26 agri-horticultural crops. His dynamic vision has resulted into diversification of the company into related areas of seed for a holistic approach towards modern agriculture with an attention on environment protection. The services of the company has reached out to cross cultural ambience of 19 Indian states with their plethora of cropping patterns through 3000 distributors and 2.5 lakh dealers to 100 lakh happy Indian farmers.

Mr.Vidyasagar is a visionary with philosophy and futuristic action plan for directing the company to be the Indian leader in seed industry. He has widely traveled countries like USA, France, Italy, UK, Australia, Greece, Germany, Canada, Japan, Thailand, China, Malaysia, Hongkong, Vietnam etc., for acquaintance with the contemporary research in those countries and for technology alliances and business development. With his vision and dynamism, the Vibha seed Group is now poised to expand its horizon globally.


Session VIII
Phytopharmaceuticals

Name	Dr. G.B.K. Rao	
Present Position & Affiliation	Chairman and Managing Director, Pragati Green Meadows and Resorts Ltd, Hyderabad	
Email	raogbk@pragatiresorts.com / raogbk@gmail.com	
Phone	91-40-2355 3183 / 3184 / 3185	
Professional Experience	1. A Technocrat and Industrialist, highly regarded Trust Specialist with 28 years of experience in financial management.	
	2. In 1996, conceptualized and created M/s Pragati Green Meadows and Resorts a 1100 acre natural wonder	
Major Contributions	1. Developed Pragati into a “one-of-its kind” resort by transforming wastelands into a lush green nature habitat.	
	2. Established Pragati Sparsh – Ayurveda, and Pragati Bio-Pharma Pvt. Ltd. a company engaged in research for enhancing technology, scaling up for drug manufacture, pharma intermediaries, herbal formulations, anti & probiotics, RNA based herbal extracts and select Ayurveda drugs.	
Highlights of achievements	1. Received the Award for Excellence in the category of Eco-Friendly Project for the year 2006-2007 from the Tourism Department, Government of Andhra Pradesh.	
	2. Award for Excellence in the category of Eco-Friendly Tourism Project for the years 2004, 2006 and 2007 from Department of Tourism, Govt. of Andhra Pradesh.	
	3. Other state recognitions for his contribution environment	
Education	BE (Mechanical Engineering)	
Professional Association		
Membership	Member of state and national industry associations and bi-lateral chambers of commerce	


Title: Pragati – The interphase between agro-biotechnology & natural remedies

Name Present Position & Affiliation	Dr. J. L. N. Sastry Director, Pragati Ayushman Pvt. Ltd. Co., Hyderabad	
Phone	0884-2342966	
Professional Experience	<ol style="list-style-type: none"> 1. Involved in teaching and has held various administrative positions in government institutions. 2. He was also associated with Dabur India Ltd as Medical Advisor and as Head, Clinical Research for & Dabur Research Foundation respectively. 3. Has been pursuing private practice since July 2007. 	
Area of Research	Ayurveda \ Herbal Medicine	
Major Contributions	<ol style="list-style-type: none"> 1. Worked with IICT, Hyderabad on HPLC fingerprinting for the dissertation work entitled "IDENTIFICATION OF MARKET SAMPLES OF PUSHKARAMULA (Inula racemosa) & KUSHATA (Saussurea lappa)" in 1996-98. 2. As the Research Projects Coordinator, Govt. Research Dept. of Ayurveda, was involved in animal safety studies, experimental studies and clinical studies. 3. Presently involved with a unique project on Heavy Metals in Plant based Medicines / Herbo-metallic formulations. 	
Number of Publications	Books – 15 Research Articles - 28 Presented papers in 14 national and 7 international seminars	
Highlights of achievements	Recipient of 7 awards	
Education	BAMS (Bachelor of Ayurvedic Medicine and Surgery), MD (Ayurveda)	
Sanskrit knowledge	VICHAKSHANA exam - from Dakshina Bharata Sanskrita Pracharini Sabha, Chittore (A.P.) - 1986-87	

Title: Farms to pharma: Intervention of agribiotechnology for medicinal plant utilization

Name	Prof. Yamini Bhusan Tripathi	
Present Position & Affiliation	Professor in Medicinal Chemistry, IMS, Banaras Hindu University, Varanasi	
Email	yaminiok@yahoo.com	
Phone	(w) 0091-542-6702171, Home-2366577, Cell-09415694450	
Fax	0542-2368174, 2366577	
Professional Experience	27 years of teaching and 23 years of research experience.	
Area of Research	Biochemistry	
Major Contributions	3 polyherbals patented for various metabolic disorders namely, atherosclerosis, diabetic nephropathy, radiation protection. Now developing new formulations as PKC inhibitor, iNOS inhibitor, COX-2 inhibitor.	
Number of Publications	81	
Patents	3	
Education	PhD: Biochemistry on thyroid functions in 1983	
Post Doc	Tbingen University-Germany, Missouri University, Columbia, USA,	

Title: Novel polyherbal food supplements for diabetes and its associated complications

Name	Abdul Manan Mat Jais	
Present Position & Affiliation	Prof, Department of Biomedical Sciences Faculty of Medicine and Health Sciences University Putra Malaysia	
Email	abmanan@medic.upm.edu.my; ammatjais@yahoo.com	
Phone	603 89468543 (office); 019 3833735 (HP)	
Fax	603 89426957 (Fac.) or 603 89436178 (Dept.)	
Professional Experience	Researcher and consultant with various administrative positions.	
Area of Research	Neurophysiology/Biomedical	
Major Contributions	<p>Involved in:</p> <ol style="list-style-type: none"> 1. Establishment of Knowledge Resources for Sciences and Technology Excellence Malaysia or KRSTE.my, for Ministry of Sciences Technology and Innovation (MOSTI). 2. ISP (ICT Strategic Planning) for Ministry of Natural Resources and Environment, 2006 and Malaysian E-government programs 3. Penulisan Buku: Makalah Ilmiah Untuk Buku 'Islam Hadhari' terbitan Yayasan Ilmuwan, 2006 4. Malaysia Quality Assurance, for Higher Education in Health Sciences since 2007 	
Highlights of achievements	<ol style="list-style-type: none"> 1. SETAC-Asia Pacific; Executive Council Since 1995 2. Excellence Services Award or Anugerah Perkhidmatan Cemerlang 1997 by UPM 3. Fellow to Malaysian Scientist Association in 1998 4. BLACPMA Executive Representative since 2006 	
Education	Ph.D. 1983 - Neurophysiology/Pharmacology University of Southampton, Southampton, ENGLAND	

Title: Natural Product is Bio-Wealth and a commodity: Haruan Channa striatus as Malaysia's chapter

Session X
Biofuels

Dr. Taher Abbasi

Co-founder and CEO, Cellworks Group Inc.



Dr. Taher Abbasi has over 17 years of technology and management experience in the semiconductor engineering/chip business; automation and life sciences enabling technology industry. Prior to starting Cellworks Group Inc., he held senior management positions in Cadence Design Systems Inc., Get2Chip Inc., ByteK Design Systems and Synopsys Inc.

Dr. Abbasi is also the co-author of the books "Logic Synthesis Using Synopsys" edition 1,2 (Kluwer Publishers) and "It's the Methodology, Stupid!" (ByteK Inc. Publication). He has also written and presented many articles in technical publications and industry conferences worldwide. Taher was an adjunct faculty in extension programs at University of California, Santa Cruz, University of California, Irvine and California State University, Northridge teaching classroom and e-learning courses on ASIC synthesis based methodology and Design for Testability. He holds a Masters degree in Computer Engineering from California State University, Northridge and a Bachelor's in Electronics from University of Bombay.

Title: High Throughput Re-Engineering Methodology Using Virtual Strains

Dr. Pogaku Ravindra

Professor, School of Engineering and Information Technology, University of Malaysia

Dr. Pogaku Ravindra is a distinguished Professor of Bioprocess Engineering, in the Chemical Engineering Program and Postgraduate coordinator at University Malaysia Sabah (UMS), Kota Kinabalu, Sabah, Malaysia. He has varied experience of over 25 years in teaching, research, industry, administrative and executive. His PhD was in Biotechnology from JNT University, Hyderabad. He was a research scientist and Post Doc at Cornell University, USA. Prof Ravindra's research interest includes bioleaching, bioremediation, wealth from waste, microbial fermentation and bioreactor technology. At present his research group focus is on Bio-derived energy. He has over 125 research publications and presentations to his credit. He has carried out around 20 national, international and industrial research projects. He was awarded with Gold and Silver medals for his research contributions at Malaysia. He has widely travelled length and breadth of the world to emphasize the need of Energy, Environment and Food for better society.



Title: Harnessing Biofuels for future generations

Mr. S. Sriram

Head, Biofuels, Tata Chemicals

Mr. Sriram completed his MBA in Finance in 1990. He has a total of 18 years of experience mainly in Corporate Finance specializing in Mergers & Acquisitions.

He has been working with Tata Group for more than 14 years, out of which he has been with Tata Chemicals for 7 years. He was actively involved in finalizing the deals of IMACID, Morocco and Brunner Mond,


UK. He is presently heading Biofuels in Tata Chemicals and is responsible for setting up a demonstration bioethanol facility in Maharashtra, India, and establishing Jatropha plantation. He is also responsible for evaluating global biofuels opportunities.


Mr. Sriram is active in various industry associations including Roundtable on Sustainable Biofuels, Biodiesel Association of India, Indian Chemicals Council and BCCI Agri Business Committee etc.



Session XII

Animal improvement and Genomics

Name	Lalji Singh	
Present Position & Affiliation	Director, Centre for Cellular & Molecular Biology (CCMB), Hyderabad	
Email	lalji@ccmb.res.in	
Phone	Phone No. 27160789 (Off); 27160555 (Res.)	
Fax	27160252	
Professional Experience	Spent 13 years in the Institute of Animal Genetics, University of Edinburgh (1974-1987) before joining CCMB.	
Area of Research	Molecular basis of Sex-determination; DNA Fingerprinting and genetic diversity; Wildlife Conservation; Human Genome Analysis and Ancient DNA Studies	
Major Contributions	Has proposed and established a new centre, the Centre for DNA Fingerprinting and Diagnostics (CDFD) at Hyderabad under the Department of Biotechnology (DBT), as an Officer on Special Duty (OSD), CDFD.	
	Based on the studies of Dr Lalji Singh and his colleagues on Wildlife Conservation, Government of India has set up a "Laboratory for the Conservation of Endangered Species (LaCONES)" in Hyderabad.	
Highlights of achievements	Recipient of several awards and honours including Padma-Shri by the President of India (2004).	
	Recipient of Fellowship of Indian and Foreign Academies	
Education	Ph.D (Cytogenetics) from Banaras Hindu University	
Professional Association		
Membership	Membership of various professional bodies such as the Association for the Promotion of DNA Fingerprinting and Other DNA Technologies; Society of Biological Chemists of India; and was President, Indian Society of Human Genetics.	
Reviewer	Editorial board of 7 journals	

<p>Name</p> <p>Present Position & Affiliation</p>	<p>Dr. Morris Agaba International Livestock Research Institute, Kenya</p>	
<p>Professional Experience</p>	<p>Has worked as a researcher at:</p> <ol style="list-style-type: none"> 1. Genome Research, International Laboratory for Research on Animal Diseases, Nairobi, Kenya; 2. Shirakawa Institute of Animal Genetics, Shirakawa. Japan; 3. Nutritional Genetics, Institute of Aquaculture, University of Stirling, Stirling, UK 4. Scientist, Genetics of Host Pathogen Interaction, International Livestock Research Institute, Nairobi, Kenya. 	
<p>Area of Research</p>	<p>Molecular Genetics of Host-Pathogen Interaction</p>	
<p>Education</p>	<p>B Vet Med (BVM), PhD</p>	

Title: New opportunities for understanding and exploiting livestock diversity

Dr. Satish Kumar


Dy. Director, CCMB, Hyderabad



Dr. Satish Kumar is a faculty at the Centre for Cellular and Molecular Biology, Hyderabad (India) heading the 'National Facility for Transgenic and Gene Knockout Mice'. His current research interests include molecular approaches in animal breeding, specifically mapping the genome of water buffalo, and functional genomics using transgenic mouse and murine embryonic stem cells. Recently, his group has created a knockout mouse strain lacking *k*-casein through embryonic stem cell technology for the first in India. He is a member of FAO /Advisory Group on Animal Genetic Diversity.

Title: Domestic Buffalo Genomics for Genetic Enhancement: Opportunities and Challenges

Session XIV
Animal Biotechnology: Diagnostics and Vaccines

Name	Prof. Rakesh Bhatnagar,	
Present Position & Affiliation	School of Biotechnology, Jawaharlal Nehru University, New Delhi	
Email	rakeshbhatnagar@mail.jnu.ac.in	
Phone	011-26704079	
Fax	011-2674-2040	
Professional Experience	Has nearly 35 years of research experience and close to 22 years of teaching experience.	
Area of Research	Biochemistry / Biotechnology	
Major Contributions	<ol style="list-style-type: none"> 1. Besides teaching, he is involved in designing and updating the the curriculum of the courses such as Biochemistry and Enzymology and Molecular Biology of Infectious Diseases. 2. Was involved in the transfer of technology for making "Genetically Engineered Vaccine against Anthrax" to M/s. Panacea Biotec Ltd., in 2001. 	
Number of Publications	International – 96 National - 6 Chapters contributed to books - 07	
Patents	3 (has filed for 13)	
Highlights of achievements	<ol style="list-style-type: none"> 1. Received Indian Council of Medical Research (ICMR) award for outstanding research work in the field of Immunology (Development of recombinant anthrax vaccine) for the year 2001, received on 14th Dec. 2003. 2. Received AA India Biotech Association Award 2001-2002, in recognition of achievements in Promotion of Biotechnology. 3. Awarded fellowship of leading institutes 4. Has completed 9 projects, funded by external agencies; 10 more projects are undergoing 	
Professional Association		
Membership	Member of nearly 20 professional bodies / associations	
Reviewer	Journals : 6	

Name: Dr. G.S.Reddy

Chief General Manager, Indian Immunologicals Limited, Hyderabad

Email: gsreddy@indimmune.com

Phone: 91-40-23000211


Fax: 91-40-23005958



Dr.G.S.Reddy obtained basic degree in Veterinary medicine in 1981 from Andhra Pradesh Agricultural University, Hyderabad.

He has 24 years of experience in industry, developing veterinary and human biologicals. Experience encompasses Quality, Research and Development, Manufacturing and Regulatory affairs. He is heading the team which is involved in manufacturing of human rabies vaccine, recombinant hepatitis B, Measles, DPT, TT, DT and DPTH vaccines. He worked on collaborative vaccine development projects with Georg August University, Gottingen, Germany and Centers for Disease Control and Prevention, Atlanta, USA. He is a co-author of patent on DNA Rabies vaccine. He has coordinated clinical trials of Rabies, Hepatitis B, Measles, DT, TT and DTP vaccines. He has published 40 scientific papers in various journals.

Title: Recent Advances in Vaccine Development

Name	Dr.D.K.Dey	
Present Position & Affiliation	General Manager- Biotechnology, Globion India Private Limited (Suguna Group), Hyderabad	
Email	dkdey@sugunapoultry.com	
Phone	040-64534030	
Fax	040--27810860	
Professional Experience	22 years in Sales and Marketing of Veterinay pharmaceuticals	
Highlights of achievements	Establishment of Veterinary vaccine manufacturing facility at Hyderabad.	
Education	Bachelor of Veterinary Science	

Title: Effective Salmonella control through vaccination in Poultry


Dr. J.C. Hodgson

Principal Scientist, (Bacteriology Division), Moredun Research Institute, UK

Dr. Hodgson is a project leader at the Moredun, studying the host response to infectious bacterial disease and identifying the key role of endotoxin in causing a range of diseases, including systemic pasteurellosis and watery mouth disease in lambs and haemorrhagic septicaemia in buffalo calves. He is currently leading the *Pasteurella* Research Group, with a major research focus on the mechanisms and epidemiology of disease during pneumonic and systemic pasteurellosis in cattle caused by *Pasteurella multocida*, using functional genomics and proteomics to identify and characterise novel surface components of pathogenic and commensal isolates of *P. multocida* and working with academic and commercial partners nationally and internationally to develop novel diagnostic and control products.



Title: Towards the development of novel vaccines against diseases of bovids caused by *Pasteurella multocida*

Name	Dr. Hongxuan He	
Present Position & Affiliation	Professor of Microbiology, National Research Center for Wildlife Born Diseases, Institute of Zoology, Beijing, China	
Email	hehx@ioz.ac.cn	
Phone	+86-10-6480 7118	
Fax	+86-10-6480 7118	
Professional Experience	Professor of Preventive Veterinary Medicine	
Area of Research	1. Molecular ecology of pathogens;	
	2. Pathogenic diversity and co-evolutionary relationship between pathogen and host;	
	3. Viral infections and trace elements: A complex interaction.	
Major Contributions	1. Developed the DNA vaccine against Avian Influenza, Cryptosporidiosis and SARS in China	
	2. Developed the first and only special lab for wildlife born diseases and established rapid diagnostic methods in the field	
Number of Publications	100 peer scientific papers in domestic and foreign Journals	
Highlights of achievements	1. Was awarded 9 S&T awards including the second prize of Science and Technology, Trade Ministry of State of P.R. China; and the second prize of Science and Technology, Henan Province, China.	
	2. Principal investigator of the Wildlife Borne Diseases Group at Institute of Zoology, Chinese Academy of Sciences since 2006.	
	3. Held and participated in nine projects	
Education	PhD in Preventive Veterinary Medicine degree,	
Post Doc	Tsinghua University and Cornell University	
Professional Association		
Membership	The Chinese Association of Zoology, Chinese Veterinary Association	
Reviewer	Edited 9 books as the editor in chief, the associate editor or member of editorial board.	

Title: RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids

Session XVI

Agri Biotech Platform: Products and Services

Mr. Vivek Singhal

President, Biotech International Limited, New Delhi

Tel.: +91-11-29220546/29220547

Fax: +91-11-29229166/29223089,

E-Mail: vsinghal@biotech-int.com/projects@biotech-int.com




Mr. Vivek Singhal President, Biotech International Limited, is the founder President of All India Biotech Association (AIBA), a non-profit Society Registered in 1994.

He has been on the Governing Council of CSIR (under Ministry of Science & Technology), and also the former Chairman of Electronics & Computer Software Export Promotion Council (ESC) and Chairman (N) of Federation of India Exports Organization (FIEO).

He has been on the Board of Directors of Bharat Sanchar Nigam Limited (BSNL), a Govt. of India undertaking and also on the Board of Directors of VSNL (a TATA Group of Companies).


He has also been on the Board of Directors of Bharat Yantra Nigam Ltd. (a very large Public Sector Undertaking) and on the Board of Directors of Indian Trade Promotion Organization (ITPO).

He has been on the Governing Body of many Institutes and a Member on the Board of Management of Guru Gobind Singh Indraprastha University.


<p>Name</p> <p>Present Position & Affiliation</p>	<p>Dr. Peter Langridge</p> <p>CEO, Australian Center for Plant Functional Genomics, University of Adelaide, Australia</p> 
<p>Professional Experience</p>	<ol style="list-style-type: none"> 1. Director of LifePrint Australia Pty Ltd, a plant DNA diagnostic company, and sits on the Management Committee of the International Triticeae Mapping Initiative (ITMI). 2. An Honorary Fellow of the Scottish Crop Research Institute and in 2007 was appointed Fellow of Food Standards Australia and New Zealand.
<p>Area of Research</p>	<p>Development and application of molecular biology to crop improvement.</p>
<p>Number of Publications</p>	<p>160</p>
	<p>He is on three journal editorial boards: Theoretical and Applied Genetics, Plant Methods and International Journal of Plant Genomics.</p>
<p>Highlights of achievements</p>	<ol style="list-style-type: none"> 1. Member of the Advisory Boards of the European Union BioExploit and the TriticeaeGenome Programs, the Australian Research Council Centre for Integrative Legume Research and the National Science Foundation Wheat Genomics Programs in the USA and the Institute for Biological, Environmental and Rangeland Sciences, UK. 2. He was on the Research Advisory Committee of the Consultative Group on International Agricultural Research's Generation Challenge Programme. 3. He was a member of the Gene Technology Technical Advisory Committee of Australia's Office of the Gene Technology Regulator since 2001. 4. In 2007 Peter was also appointed Chair of the Biological Sciences Panel for the Australian Research Quality Framework.

Title: Genetic and genomic approaches to improve abiotic stress tolerance in cereals

Peter Langridge

Name	Dr. S. R. Rao	
Present Position & Affiliation	Scientist G, DBT, Govt. of India	
Email	srrao@dbt.nic.in	
Professional Experience	<p>He served in various positions in Department of Biotechnology, Ministry of Science and Technology, Government of India since 1989 and was actively involved in establishment of oil palm cultivation in India.</p> <p>He served as Adviser for Science and Technology for a period of three years ((2004- 2007) years to Minister for Science and Technology, Govt. of India.</p>	
Area of Research	Specializes in core and cross-sectoral policy issues of Biotechnology development, regulation, safety, public private partnership, international relations and biotech R&D Innovation and Development.	
Major Contributions	<p>Was actively involved in establishment of oil palm cultivation in India, several sophisticated biotech infrastructure facilities.</p> <p>During 2004- 2007, he initiated important programmes on public health access in villages through public-private partnerships, S&T interventions in judiciary reforms, technology assessment of bioenergy and biofuel resources and various issues of S&T and public policy interface.</p>	
Number of Publications	30 in national / international journals	
Education	Ph.D in Mycology and Plant Pathology from Indian Agricultural Research Institute, New Delhi	
Post Doc	Fellow in Tottori University, Japan and visiting Scientist at Waite Agricultural Experimental station, Adelaide Australia	
Professional Association		
Membership	<p>Technical Committees of the Government of India; coordinator in DBT for the establishment of National Biotechnology Regulatory Authority and new biotechnology regulatory Bill.</p> <p>Academic /research councils of Universities/institutions</p> <p>Elected Member-Asia in UN Environmental Programme and other international bodies</p>	

Title: Strategic outlook on agricultural biotechnology platforms, research resources, facilities and services for translation research, technology development and diffusion

Name	Dr. Kiran K. Sharma	
Present Position & Affiliation	Principal Scientist, (Cell & Molecular Biology) Genetic Transformation Lab, ICRISAT, Andhra Pradesh India	
Email	K.SHARMA@CGIAR.ORG	
Phone	+91(40)30713300 (Work) +919849548540 (Mobile)	
Fax	+91 (40)30713074	
Professional Experience	Has been closely associated with various programs of ICRISAT since 1992. Prior to this, he worked as a Research Associate, University of Calgary, Canada.	
Area of Research	<ol style="list-style-type: none"> 1. Experimental Plant Morphogenesis. 2. Plant genetic engineering for crop improvement. 3. Translation of concepts of genetic engineering into commercial products. 4. Business incubation through Public-Private sector partnerships 	
Major Contributions	<ol style="list-style-type: none"> 1. Involved in conceptualizing and setting-up of an Agri-Business Incubator (ABI) at ICRISAT. 2. Involved in the conceptualization of a Platform for the Translational Research on Transgenic Crops which is currently being set-up at ICRISAT. 	
Number of Publications	Over 90 research papers and reviews in International Publications and books	
Education	Ph.D in Botany (University of Delhi)	
Post Doc	Biotechnology	
Professional Association		
Membership	Member of several governmental, institutional and private sector committees	

Title: Translational platform for transgenic crops: an initiative at ICRISAT